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                                                          1.  INTRODUCTION 
 
         Rheumatoid arthritis is an autoimmune disease in which there is joint inflammation, 
synovial proliferation and destruction of articular cartilage
1
. It is a disabling and painful 
inflammatory condition, which can lead to substantial loss of mobility due to pain and joint 
destruction.  
         Inflammation is a bodily response to injury, infection or destruction characterized by heat, 
redness, pain, swelling and disturbed physiological functions. Inflammation is normal protective 
response to tissue injury caused by trauma, noxious chemical or microbial agent. It is body 
response to inactivate or destroy the invading organisms, to remove the irritant and set the stage 
for the tissue repair. It is triggered by the release of chemical mediators from injured tissue and 
migrated cells
2
. 
           It is a common disease having peak incidence in 3
rd
 to 4
th
 decades of life with 3-5 higher 
preponderance in female
3
. 
           The most frequently affected joints are those of fingers and toes, wrists, knees, and ankles. 
Extra articular manifestations may occur and are frequently present in patients with severe 
disease which include ocular, pulmonary, hematologic, vascular, cardiac, neurologic and 
mucosal tissue. 
 
 The drugs commonly in use for the treatment of Rheumatoid arthritis include, 
 Glucocorticoide (e.g Cortisone and prednisone) 
 Non-steroidal anti-inflammatory drugs (NSAIDs e.g ibuprofen and Naproxone etc.,)                                     
 Biological response modifier (e.g Tumour necrosis factor- alpha blocking agents).  
 Disease-modifying anti rheumatic drugs (DMARDSs: e.g Methotrexate (MTX) and  
Leflunomide) 
 
           
          Herbal medicine, sometimes referred to as Herbalism or Botanical Medicine, is the oldest 
form of healthcare known to mankind. Herbs had been used by all cultures throughout history for 
their therapeutic or medicinal value. An herb is a plant or plant part valued for its medicinal, 
aromatic or savoury qualities. Herbal plants contain therapeutically active chemical substances 
that act upon the body
4
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        Herbal medicines widely used in health-care in both developed and developing countries are 
complex chemical mixtures prepared from plants and are limited in their effectiveness because 
they are poorly absorbed when taken orally. 
           
         Herbal formulations have reached widespread acceptability as therapeutic agents for 
diabetic, arthritics, liver diseases, cough remedies, memory enhancers and adoptogens. 
            As per WHO definition, there are three kinds of herbal medicines: 
                                     Plant material 
                                     Processed plant material  
                                     Herbal products. 
 
          Herbal medicine products are dietary  supplements that people take to improve their health 
and are sold as tablets, capsules, powders, teas, extracts and fresh or dried plants. 
          According to an estimate of the World Health Organization (WHO), about 80% of the 
world population still uses herbs and other traditional medicines for their primary health care 
needs
5
 
                      
        Herbal medicine is a major component in all indigenous people traditional medicine and a 
common element in Ayurvedic, Homeopathic, Naturopathic. WHO notes that of 119 plant-
derived pharmaceutical medicines, about 74% are used in modern medicine in ways that 
correlated directly with their traditional uses as plant medicines by native cultures. Major 
pharmaceutical companies are currently conducting extensive research on plant materials 
gathered from the rain forests and other places for their potential medicinal value
6
. 
 
          In the 20
th
 century much of the pharmacopoeia of scientific medicine was derived from the 
herbal lore of native peoples. Many drugs commonly used today are of herbal origin. About 25% 
of the prescription drugs dispensed in the United States contain at least one active ingredient 
derived from plant material. Some are made from plant extracts; others are synthesized to mimic 
a natural plant compound. It was an integral part of the development of modern civilization
7
.  
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Types of Herbal Medicine 
          Traditional Chinese Herbalism which is part of Traditional oriental Medicine, Ayurvedic 
Herbalism which is derived from Ayurvada and western Herbalism which is originally came 
from Greece and Rome to Europe and then spread to North and South America. Chinese and 
Ayurvedic Herbalism have developed into highly sophisticated systems of diagnosis and 
treatment over the centuries. Western Herbalism is today primarily a system of folk medicine
8
 
 
Advantages of Herbal Medicine
9
 
 Herbal medicine have long history  of use and better patient tolerance as well as 
acceptance 
 Medicinal plants have a renewable source, which is our only hope for sustainable 
supplies of cheaper medicines for the world growing population. 
 Availability of medicinal plants is not a problem especially in developing countries like 
India having rich agro-climatic, cultural and ethnic biodiversity 
 The cultivation and processing of medicinal herbs and herbal products is environmental 
friendly 
 Cost-effectiveness-prescription drugs cost much more money than herbal medicines 
 Lower side effects herbal medicines are generally a far heal their solution than 
prescription drugs due to potential harmful side effects caused by unpredicted body 
chemistry interactions 
 
Disadvantage of Herbal Medicines 
 Procedures for pure and genuine herbs are not available, so sub-standard and spurious 
herbs are there in the market 
 Identification of exact mechanism and pharmacology of all herbal medicine is not 
available 
 Adulteration ratio is very high 
 Clinical and toxicological data was not available for all herbal medicine 
 There is no much information available on the safety measures 
 All herbal medicine are not tested with important parameters like microbial content, 
heavy metals content and pyrogens etc.  
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Herbal Medicine Today
10
 
                As the world modernized, so did herbal medicine. Laboratories produce synthetic 
medicines but there may be underlying side effects to the body. This is because they contain rich 
concentrations of chemical substances. 
 
                Chemists have analysed the components of herbs, then isolated and extracted the 
healing properties. The chemical moiety responsible for efficacy was synthesized in modern 
laboratories so they can be incorporated into to the modern medicines. Several herbal 
preparations are made in to pills, tablets and capsules, but still have the same benefits derived 
from natural herbs. 
Herbal formulation
11
 
                    An herbal „formula‟ consists of a selective combination of individual herbal 
ingredients that are formulated for a specific ailment or group of disease-conditions. When herbs 
are combined together, they become more potent and effective within the body than single herb 
due to their activating or catalyzing influence upon one another. These combinations acts as 
powerful catalysts (with synergistic effects) in order to activate over own individual healing 
energies (or vital force) which permeate the entire organism and reside in each and every cell in 
our bodies. 
 
The Capsule Dosage form
12
 
                    The word “capsule” in the English language is derived from the Latin word 
“Capsula”, which means a small box or container in more recent times, capsule has been used 
primarily to describe a solid oral dosage form, which consists of a container, usually made of 
gelatin filled with a medicinal substance. There are many forms of capsules and they can be 
divided into two main categories, which in current English usage are described by the adjectives 
“hard” and “soft”. The „hard capsule‟ consists of two separate parts, each semi-closed cylinder in 
shape. One part the „cap‟, has a slightly larger diameter than the other, which is called the „body‟ 
and is longer the cap fits closely over the body to form a sealed unit. 
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               The soft gelatin capsule is also called as „one piece‟. Capsules are available in many 
size to provide dosing flexibility. Unpleasant drug tastes and odours can be masked by the 
tasteless gelatin capsules is one of the most frequently utilized dosage forms. 
      
               Hard gelatin capsules can be filled with a large varity of materials of different 
physicochemical properties (i.e dry solids, semi solid, non-aqueous liquids, etc) while soft 
gelatin capsule are generally used to contain liquid and semisolid materials. 
 
Capsules offer many advantages 
 Capsules, because of their elongated shape, are easy to swallow, which is one reason for 
the number of capsules- shaped tablets manufactured today. 
 Flexibility of formulation is another advantage of the capsule dosage form. Howeverthe 
biggest formulation advantage of capsules is that there is less need for additional 
excipients. 
 Since capsules are tasteless, they effectively mask any unpleasant taste or odour of their 
contents. 
 They offer rapid release characteristics, due to the rapid dissolution rate of the capsules 
 The use of hard capsules is also a common feature in clinical trials, as the filling of 
tablets or even capsules themselves will blind the dosage forms studied. 
 The manufacture of capsules is much shorter process compared to that for other modern 
dosage forms (e.g Tablet). 
 Controlled release can be achieved using capsules. Dry powder mixtures, granules, 
pellets and tablets can be filled into hard capsules. Moreover combination of two or three 
types (dry powder mixtures, tablets or pellets) also can be put into capsules. 
 
Disadvantage of capsule 
 The drugs which are hygroscopic absorb water from the capsule shell making it brittle 
and hence are not suitable for filling into capsules. 
 The concentrated solutions which require previous dilution are unsuitable for capsules 
because if administered as such lead to irritation of stomach. 
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     Standardization of Herbal Drugs
13
 
                 “Standardization” of herbal drugs is not an easy task as numerous factors influence the 
bio efficacy and reproducible therapeutic effect. In order to obtain quality oriented herbal 
products, care should be taken right from the proper identification of plants, season and area of 
collection, their extraction, purification process and rationalizing the combination in case of 
polyherbal drugs. Standardization means adjusting the herbal drugs preparation to a define 
content of a constituent or a group of substances with known therapeutically activity respectively 
by adding excipients or by mixing herbal drugs or herbal drug preparation. 
                   “Evaluation” of a drug means confirmation of its identity and determination of its 
quality and purity and detection of its nature of adulteration.
14
 
 
Importance of standardization
15
 
  Quality control standards are very vital in developing the herbal formulations, 
 To ensure batch to batch uniformity in contents. 
 Confirmation of correct amount of dosage or extract per dosage unit. 
 Positive control to indicate possible loss or degradation during manufacturing. 
 
Two types of Standardization
16
   
            In the first category, “true” standardization, a definite phytochemical or group of 
constituents is known to have activity. Ginkgo with its 26% ginkgo flavones and 6% terpenes are 
the classic example. These products are highly concentrated and no longer represent the whole 
herb and are now considered as phytopharmaceuticals. In many cases they are vastly more 
effective than the whole herb. 
 
            The other type of standardization is based on manufacturers guaranteeing the presence of 
a certain percentage of marker compounds; these are not indicators of therapeutic activity or 
quality of the herb. 
 
Quality Control of Herbal Medicine
17
 
              Quality can be defined as the status of a drug that is determined by identity, purity, 
content, and other chemical, physical and biological properties or by the manufacturing  
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processes. Quality control is a term that refers to processes involved in maintaining the validity 
of a manufactured product. 
 
WHO Guidelines for Standardization of Herbal Formulation 
 Quality control of crude drugs materials, plant preparations and finished products. 
 Stability assessment and shelf life. 
 Safety assessment; documentation of safety based on experience or toxicological studies. 
 Assessment of efficacy by ethno medical information and biological activity evaluations.    
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                                          2. REVIEW OF LITERATURE 
 
 
Smilax zeylanica 
 
 
       Anita murali et al (2000) reported that  antioxidant activity  and HPTLC  Studies  on the 
root and rhizomes of Smilax zeylanica.
18
 
     SN Yoga narasimhan et al (2010) reported that pharmacognostical study of  root and 
rhizomes of  Smilax zeylanica.
19
 
     Prabhat kumar jena et al (2011) reported that phytochemical investigation and  
simultaneous study on antipyretic, anticonvulsant activity of leaves of  Smilax zeylanica.
20
 
     Anita murali et al (2012) reported that hepato-protective activity of root and rhizomes of 
Smilax zeylanica.
21
 
      Sanjib saha et al (2013) reported that analgesic and antibacterial activity of leaves of  Smilax 
zeylanica 
22
 
 
Lippia nodiflora 
 
       Ashokkumar et al (2001) reported that antioxidant activity of leaves of lippia nodiflora
23 
       Asish tulshkar and Vijaya et al (2009) reported that neuropharmacological activity of 
leaves of lippia nodiflora
24 
       Balamurugan et al (2011) reported that antidiabetic activity in leaves of lippia nodiflora
25 
       Alireza ivanbakhsh et al (2012) reported that antimicrobial activity of leaves & flowers of 
lippia nodiflora
26
. 
       Thomsan et al (2013) flavonoid fraction of hepatoprotective activity of leaves lippia 
nodiflora
27
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Asparagus racemosus 
          Hossain et al (2012) reported that cytotoxicity and in vitro antioxidant activity of 
Asparagus racemosus root extract.
28
 
          Ravishankar et al (2012) reported that preliminary phytochemical screening and in vitro 
antibacterial activity on Asparagus racemosus root.
29
 
           Januj joshi et al (2011) reported that anti stress activity of ethanolic extract of Asparagus 
racemosus willd root in mice.
30
 
            Javeed ahmed wani et al (2011) reported that phytochemical screening and aphrodisiac 
activity of Asparagus racemosus root.
31
 
            Ramachandran vadivelan et al (2011) reported that antioxidant and hypolipidemic 
activity of Asparagus racemosus on streptozotocin induced diabeticin rats.
32
 
 
Bacopa monneri 
            R.K Goel et al (2000) reported that evaluation of in-vivo wound healing activity of 
Bacopa monnieri on different wound model in rats.
33
 
          Gopalakrishnan et al (2010) reported that potential effect of hepatoprotective activity of 
Bacopa monnieri on nitrobenzene induced liver damage in rats.
34
 
           Abhishek mathur et al (2010) reported that pharmacological investigation of Bacopa 
monnieri on the basis of antioxidant, antimicrobial & anti inflammatory activity.
35 
          Sudha et al (2002) reported that anti convulsant activity of different extracts of Bacopa 
monnieri in animals.
36
 
          Aamir nazir et al (2001) reported that anti parkinsonian effects of Bacopa monnieri 
insights from transgenic and pharmacological caenorhabditis elegans models of parkinson’s 
disease.
37
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Allium sativum 
 
 
             Meriga.B et al (2012) reported that insecticidal, antimicrobial and antioxidant activities 
of bulb extracts of allium sativum.
38
 
              Asaduzzaman et al (2010) reported that evaluation of antidiabetic, antihyperlipidemic 
and Hepatoprotective effects of alloxan induced diabetic rats.
39
 
              Ejaz et al (2003) reported that extract of Allium sativum in cancer chemoprevention.
40
 
            Venkatesh et al (2010) reported that identy of the immunomodulatory proteins from 
Allium sativum with the major garlic lectins or agglutinins.
41
 
             Belguith et al (2010) reported that study of the effect of aqueous garlic extract Allium 
sativum on some salmonella serovars isolates.
42
 
 
 
Oldenlandia heynei 
      Abdur Rashid M et al (2010) reported that Hepatoprotective and antibacterial activity of 
ursolic acid extracted from Oldenlandia heynei
43
 
       Pandian S et al (2013) reported Hepatoprotective activity of methanolic extract of 
Oldenlandia heynei against D-galactosamine induced rat.
44
 
        Ahmad sazali hamzah et al (1998) Chemical constituent of Oldenlandia heynei Asean 
Review of Biodiversity and Environmental Concervation (ARBEC).
45
 
        Sigaravelu P, Shrishailappa B, Subban R. in vitro anti oxidant activity of Oldenlandia 
heynei www.ncbi.nlm.nih.gov (Bubmed).
46
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                                                   3. AIM AND OBJECTIVE 
 
 
          The aim of present study is to formulate an ayurvedic capsule for treatment of 
arthritis. 
          The formulated capsules are evaluated as per WHO guidelines and also performed 
pharmacological activity.  
 
  
The objectives of the study were  
 
1. Raw material analysis 
 Studying the raw materials or ingredients of the formulation by carrying out the  
                    Preliminary raw materials analysis. 
 
2. Preformulation development 
 To formulate a capsule with six herbs by using preformulation studies.  
 
3. Standardization of the best batches  
  To standardise the physico-chemical parameters of the capsule. 
 To analyse and Quantify of the presence of phytoconstituents in the capsule.  
 To analyse the fingerprint using HPTLC for the polyherbal formulation.  
 Establishing the safety pertaining to heavy metals, pesticide residue and microbial 
load analysis.  
 
4. Stability studies  
 
 Establishing stability of the formulation under accelerated condition of Temperature 
and humidity as per ICH guidelines. 
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 5. Pharmacological evaluation of the formulation  
 Acute toxicity studies  
 Anti arthritic activity of the formulation using in vitro Parameters such as protein                    
denaturation, Proteinase inhibitory activity and Membrane stabilization activity.  
 In vitro antioxidant activity of the formulation such as reducing power assay, nitric oxide 
scavenging assay. 
 Evaluation of the formulation for arthritic activity by adjuvant induced arthritis model in 
rats.  
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                                             4.  DISEASE PROFILE
47,48
 
 
 
INTRODUCTION 
               Rheumatoid arthritis is a chronic inflammatory disease of unknown etiology marked by 
a symmetric, peripheral polyarthritis. 
               It is the most common form of chronic inflammatory arthritis and often results in joint 
damage and physical disability. Because it is a systemic disease, Rheumatoid arthritis may result 
in a variety of extra articular manifestations, including fatigue, subcutaneous nodules, lung 
involvement, pericarditis, peripheral neuropaty, vasculitis and hematological abnormalities. 
 
CLINICAL FEATURES 
             The incidence of Rheumatoid arthritis increases between 25 and 55 years of age, after 
which it plateaus until the age of 75 and then decreases. 
             The presenting symptoms of Rheumatoid arthritis typically results from inflammation of 
the joints, tendons and bursae. 
             Patients often complain of early morning joint stiffness lasting more than 1 hour and 
easing with physical activity. 
             The earliest involved joints are typically the small joints of the hands and feet. 
             The initial pattern of joint involvement may be monoarticular, oligoarticular (≤ 4 joints), 
or polyarticular (> 5 joints), usually in a symmetric distribution. 
EPIDEMIOLOGY 
             Rheumatoid arthritis affects approximately 0.5- 1% of the adult population world wide. 
Like many other autoimmune disease, Rheumatoid arthritis occurs more commonly in females 
than in males with a 3:1 ratio 
             Most of the theories center on the role of estrogens in enhancing the immune response. 
For example some experimental studies have shown that estrogen can stimulate production of 
tumor necrosis factor α (TNF α), a major cytokine in the pathogenesis of Rheumatoid arthritis. 
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ENVIRONMENTAL FACTOR 
        In addition to genetic predisposition, a host of environmental factors have been implicated 
in the pathogenesis of Rheumatoid arthritis. 
       The most reproducible of these environmental links is cigarette smoking. 
HEMATOLOGY 
         A normochromic, normocytic anemia often develops in patients with rheumatoid arthritis 
and is the most common hematologic abnormality. The degree of anemia paralles the degree of 
inflammation, correlating with the levels of serum C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR). Platlet counts may also be elevated in rheumatoid arthritis as an acute               
phase reactant. Immune mediated thrombocytopenia is rare in this disease.  
PATHOLOGY  
          The pathologic hallmarks of RA are synovial inflammation and proliferation, focal bone 
erosions, and thinning of articular cartilage. 
         Chronic inflammation leads to synovial lining hyperplasia and the formation of pannus, a 
thickened cellular membrane of granulation- reactive fibrovascular tissue that invades the 
underlying cartilage and bone. 
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Fig 4.1 shows the pathological changes of rheumatoid arthritis joint in comparison with normal 
joint 
 
                                                                         
                    Fig 4.2 Rheumatoid arthritis of toes and fingers joint 
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MEDIATORS OF INFLAMMATION 
                                       Table 4.1Mediator of inflammation 
Mediator Principle sources Actions  
Cell derived 
Histamine Mast cell, basophils, 
platelets 
Vasodilation, vascular permeability 
endothelial activation. 
Serotonin  platelets Vasodilation,vascular permeability  
Prostaglandins  Mast cell, leukocytes Vasodilation, pain,fever  
Leukotrienes  Mast cell, leukocytes vascular permeability, chemotaxis, 
leukocyte adhesion and activation. 
Platelet-activating 
factor 
Mast cell, leukocytes Vasodilation,vascular permeability 
leukocyte adhesion, chemotaxis, 
degranulation,oxidative burst.  
Nitric oxide Endothelium, 
macrophages 
Vascular smooth muscle relaxation, 
killing of microbes 
Cytokines (TNF, IL-1) Endothelium, 
macrophages 
Local endothelial activation, 
fever,/pain/anorexia/hypotenstion,shock 
Chemokines Leukocytes, activated 
macrophages 
chemotaxis, leukocyte activation. 
Plasma protein derived 
Kinins Plasma (produced in liver) Smooth muscle contraction, vasodilation, 
pain. 
Protease activated 
during coagulation 
Plasma (produced in liver) endothelial activation,leukocyte 
recruitmant 
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DIAGNOSIS 
     The clinical diagnosis of Rheumatoid arthritis is largely based on sings and symptoms of a 
chronic inflammatory arthritis, with laboratory and radiographic results providing important 
supplemental information. 
      The new criteria include a positive test for serum anti cyclic citrullinated peptide antibodies 
as an item, which carries greater specificity for the diagnosis of Rheumatoid arthritis than a 
positive test for rheumatoid factor. 
       Table 4.2 Classification criteria for Rheumatoid factor 
Classification Rheumatoid Factors Score  
Joint involvement One large joint 
(shoulder, elbow, hip, knee, ankle) 
0 
2-10 large joints 1 
1-3 small joints(Thumb, Wrists) 2 
4-10 small joints 3 
>10 joints 5 
Serology  Negative RF and negative ACPA  0 
Low (+) RF or low (+) anti CCP 
antibodies(≤3 times ULN) 
2 
High positive RF  or high (+) anti 
CCP antibodies (>3 times ULN) 
3 
Acute phase reactant Normal CCP and normal ESR 0 
Abnormal CRP or normal ESR 1 
Duration of symptoms < 6 weeks 0 
≥6 weeks 1 
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LABORATORY FEATURES  
 Synovial fluid analysis 
 Joint imaging 
 Plain radiography 
 MRI 
 Ultrasound 
TREATMENT  
 Non Steroidal Anti- inflammatory Drugs 
 Glucocorticoid 
 DMARDS(Disease modifying antirheumatic drugs) 
 Hydroxyl chloroquine 
 Sulfasalazine 
 Methotrexate 
 Leflunomide 
 Anti TNF α agent 
o Infliximab  3 mg/kg  
o Etanercept  50 mg 
o Golimumab 50 mg 
o Certolizumab 400 mg 
o Abatacept 500 mg 
o Anakinra 100 mg 
o Vituximab 1000 mg 
o Tocilizumab 4-8 mg/kg 
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                                   5. PLANT PROFILE49,50,51 
 
5.1 Smilax zeylanica                      
                                                          
                                   
 
     Synonym   : Smilax macrphylla Roxb., 
     Family   : Smilacaceae 
     Part used   : Root 
     Vernacular name 
     Hindi   : Kumarika  
     Siddha/ Tamil  : malattamari, kattu kodi  
     Sanskrit   : vanamadhusnahi  
     Marathi   : Kaitha  
     Telugu   : Karivilanti  
     Kannada   : Kodadantena  
     
Macroscopy  
               Plants will grow as shrubs, A large climber; stems smooth, steriate, armed with a few 
small distant prickles or almost unarmed. 
 
 Phytochemical constituent: 
               Steroids, Terpenoids, Alkaloids, Flavones, Tannins, Phenolics and Saponins. 
  
Therapeutic uses: 
               veneral disease,  rheumatic swellings, given in urinary complaints and dysentery.  
 
Dose:     50-100 mg 
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5.2 Asparagus racemosus 
 
                                     
 
  Synonym   : Protasparagus racemosus (willd.)            
  Family   : Liliaceae                
  Part used   : Root                  
Vernacular name 
 Hindi    : Marchuba                             
 Siddha/ Tamil  : Thanneer vittan kizhangu, ammaikodi.                
 Sanskrit   : Shatavari  
 Kannada   : Ashadhi  
 Marathi   : Shatavari mool 
 Telugu   : Pillipichara 
Macroscopy  
             A loose network of hyphae accumulated at the root surface, and coils formed around root 
hairs and external to epidermal cells overlying short cells of the dimorphic, suberized exodermis. 
  
Phytochemical constituent: 
              Asparagamine A, Polycyclic alkaloid, Two new steroidal saponins- shatavaroside A and 
B, Polysacchrides, Mucilage, Sterols and Isoflavone. 
 
Therapeutic uses: 
              Treatment of gastric ulcer, dyspepsia, galactogogue, stomach spasms, nervous disorders, 
cancer, diarrhea, bronchitis, rheumatism, anti-inflammatory, diabetis, tuberculosis.  
 
Dose:   16-32 mg/kg; Decoction- 50-100 ml. 
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5.3 Lippia nodiflora 
                                                                                         
 
Synonym   : Lippia nodiflora var  
Family    : Verbenaceae  
Part used   : Leaves 
Vernacular name 
Sanskrit   : Vasir vasuka  
Hindi    : Bhuiokra  
Siddha/ Tamil   : Podutalei  
Marathi   : Ratolia  
Telugu    : Bokkena 
 Kannada   : Nelahippali 
Macroscopy  
                Leaves arise in pairs at stem nodes and are rounded 10-20 mm long, 3-7 mm wide 
entire or bluntly toothed at the tip and narrow towards the petiole (2-5mm) at the leaf base, 
leaves having a grayish green appearance due to a covering of fine hairs on their surface. 
Phytochemical constituent: 
                Tannins, Saponins, Flavonoids, Alkaloids, Phenolic Compound, Triterpenoid, Steroid, 
Nodifloretin, Beta Sitosterol Glycoside, Stigmasterol Glycoside, Nodifloridin A And B along 
with Maltose, Lactose, Fructose, Xylulose Etc. 
 Therapeutic uses: 
               Snake bite, Leaves are used in asthma, rheumatism and fever. Anti fungal, skin 
problem, diuretics, hepato-protective, anti oxidant, diabetic, hypolipidaemic. 
Dose    30-150 mg  
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5.4 Oldenlandia heynei 
 
                                      
 
     Synonym   : Hedyotis herbacea L     
     Family   : Rubiaceae 
     Part used   : Leaves 
     Vernacular name 
     Hindi   : Paper-Bhed 
     Siddha/ Tamil  : Nonganam Pillu  
     Sanskrit   : Chhayaparpatika 
     Marathi   : Papti 
     Telugu   : Verri Nelavaeu, Thella Nela Vaemu 
     Kanna   : Dakaag Purale 
Macroscopy  
          Much branched, erect herbs, stem 4 angled, narrowly winged along angles. 
         Leaves sessile 1.5-3 × 0.1-0.3 cm, linear- lanceolate, acute at apex, glabrous, 3-4 setose on 
margins. 
 
Phytochemical constituent: 
              Glycosides it contains Phenolic Glycoside, Flavanoidal Glycoside. 
 
Therapeutic uses: 
               Bronchial asthma, rheumatism, varicose veins, syphills, gout, bone disorders, 
ulcer,fluid retention. 
Dose: 100-200 mg. 
 
                                                                                                   PLANT PROFILE 
 
Dept. of Pharmacognosy, COP,MMC Page 23 
 
 
5.5 Allium sativam L 
 
                                     
 
     Synonym    : Allium controversum 
     Family   : Liliaceae 
     Part used    : Bulb  
     Vernacular name 
     Hindi   : Lahsan 
     Siddha/ Tamil  : Vellai poondu    
     Sanskrit   : Arishtha 
     Marathi   : Ghagra 
     Telugu   : Korralu 
     Kannada   : Belluli 
Macroscopy  
              Rounded, composed of up to bout 15 smaller bulblets known as cloves. cloves and bulbs 
are covered by a whitish or pinkish tunic(papery coat) 
 Phytochemical constituent: 
              Allicin, Sulfur compound Allin, Peptides, Steroids, Terpenoids, Flavonoids, Phenols. 
Therapeutic uses: 
             Anthelminic, increase appetite, Bronchitis, inflammation, piles, leucoderma, asthma, 
carminative, paralysis, pain in the body and joints, chronic fevers, High blood pressure treatment, 
warts treatment, Diabetes, upper respiratory tract infection, cholesterol treatment.etc. 
Dose:   600- 1200 mg 
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5.6 Bacopa monnieri (L) Pennell 
 
                                      
 
     Synonym    : Lysimachia monnieri (L)  
     Family    : Scrophulariaceae 
     Part used   : Leaves 
     Vernacular name 
     Hindi   : Brahmi 
     Siddha/ Tamil  : Nirbrahmi             
     Sanskrit   : Jalasaya 
     Marathi    : Brahmi 
     Telugu    : Sambrani chettu 
     Kannada   : Jalabrahmi 
Macroscopy  
              A small, creeping herb, its stems are obtuse- angular, the leaves are short- petioled, 
cuneate to obovate, the capsules are ovoid. It can be easily grown in damp areas and can be 
propagated using seeds or vegetatively. 
 Phytochemical constituent: 
               Alkaloid (Brahmine and Herpestine), Saponins, Flavonoids (Leuolin& Apigenin), 
Betulic acid, Stigmasterol, Beta sitosterol, Bacosaponins- Bacosaponin F&E, 
Bacopasiden,III,IV,V, Monnierin. 
Therapeutic uses: 
               Epilepsy, asthma, ulcers, tumors, leprosy, anemia antioxidant, joint pain (rheumatism), 
Brain tonic, cardio tonic, diuretic. 
Dose    :         300 mg 
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                                              6. PLAN OF WORK  
 
 
        ANALYSIS OF RAW MATERIALS. 
 
 
 
 
 
 
PREFORMULATION STUDIES AND 
FORMULATION DEVELOPMENT. 
 
                                                         
 
 
 
 
 
STANDARDISATION OF FINISHED 
PRODUCT. 
 
 
 
 
 
 
             
ACCELERATED STABILITY STUDIES. 
 
 
 
 
.  
 
 
PHARMACOLOGICAL EVALUATION. 
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6.1 ANALYSIS OF RAW MATERIALS. 
 
       For the formulation of the polyherbal capsules, crude herbal drugs were used for 
powder in dry form. 
 Asparagus racemosus 
 Allium sativum  
 Bacopa monnieri. 
 Lippia nodiflora 
 Oldenlandia heyneii 
 Smilax zylanica 
 
 FOR CRUDE DRUG  ANALYSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Foreign organic matter  
  Loss on drying  
 
Determination of Ash value  
  Total ash  
  Acid insoluble ash  
  Water soluble ash  
 Sulphated ash  
 
Extractive value 
 Water soluble extractive  
  Alcohol soluble extractive  
 
Crude fiber content determination 
      Fluorescence analysis  
      Phytochemical studies  
      Heavy metal analysis  
      Microbial load analysis 
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PREFORMULATION STUDIES  
 
 
 
 
 
 
FORMULATION DEVELOPMENT 
 
  
 
 
 
BULK DENSITY TAPPED DENSITY 
COMPRESSIBILITY INDEX HAUSNER’S RATIO 
ANGLE OF REPOSE  
SELECTION OF ACTIVE INGREDIENTS    AND 
EXCIPIENT 
PREPARATION OF GRANULES           -   
 TRIALS- I,II,III,IV,V  
CAPSULE FILLING:  
OPTIMIZED BATCH 
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6.2 STANDARDISATION OF FINISHED PRODUCT 
 
 
 
  
 
o Description 
o Uniformity of weight 
o Disintegration test 
o Moisture content Determination 
o pH 
o Total ash 
o Acid insoluble ash  
o Water soluble ash  
o Sulphated ash ash  
o Water soluble extractive  
o Alcohol soluble extractive  
o Crude fiber content determination 
o Preliminary phytochemical   
evaluation 
o Quantitative estimation of 
phytoconstituent  
       Total alkaloids content 
       Total saponins content 
       Total flavanoids content 
       Total tanins content 
       HPTLC Fingerprinting 
       Heavy metal analysis 
       Microbial load analysis 
       Determination of pesticide residue 
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6.3 ACCELERATED STABILITY STUDIES. 
 
INITIAL STUDY 
 
30 DAYS 60 DAYS 90 DAYS 
 
Description 
Uniformity of weight 
Loss on drying 
Disintegration test 
PH 
Total ash 
Acid insoluble ash 
Water soluble ash 
Sulphated ash 
Water soluble extractive 
Alcohol soluble extractive 
Crude fiber content 
Total saponins content 
Total flavanoids content 
Total tanins content  
Total alkaloids content 
 
 
 
Description 
Uniformity of weight 
Loss on drying 
Disintegration test 
PH 
Total ash 
Acid insoluble ash 
Water soluble ash 
Sulphated ash 
Water soluble extractive 
Alcohol soluble extractive 
Crude fiber content 
Total saponins content 
Total flavanoids content 
Total tanins content  
Total alkaloids content 
 
 
Description 
Uniformity of weight 
Loss on drying 
Disintegration test 
PH 
Total ash 
Acid insoluble ash 
Water soluble ash 
Sulphated ash 
Water soluble extractive 
Alcohol soluble extractive 
Crude fiber content 
Total saponins content 
Total flavanoids content 
Total tanins content  
Total alkaloids content 
 
 
Description 
Uniformity of weight 
Loss on drying 
Disintegration test 
PH 
Total ash 
Acid insoluble ash 
Water soluble ash 
Sulphated ash 
Water soluble extractive 
Alcohol soluble extractive 
Crude fiber content 
Total saponins content 
Total flavanoids content 
Total tanins content  
Total alkaloids content 
 
  
 
6.4 PHARMACOLOGICAL EVALUATION. 
 
 
 
 
 
 
IN VITRO 
 ANTI ARTHRITIC 
EVALUATION: 
• Inhibition of Protein 
Denaturation. 
 
• Protenase inhibitory 
assay 
 
• Membrane 
stabilization 
INVITRO 
ANTIOXIDANT 
EVALUATION OF 
CAPSULE 
• Nitric oxide 
scavenging assay 
 
• Reducing power assay 
IN VIVO 
ANTIARTHRITIC 
EVALUATION 
• Acute Toxicity Study  
 
 
• Evaluation of anti 
arthritic activity using 
COMPLETE 
FRAUND’S    
ADJUVANT induced  
arthritic rats 
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                                     7. MATERIALS AND METHODS 
  
    LIST OF MATERIALS AND THEIR USES IN FORMULATION: 
  
            The materials used in the study were as follows: 
 
                        Table 7.1   List of materials and their uses in the formulation   
Name of the Materials Manufacturer/Supplier  
 
Category  
 
Asparagus racemosus 
 
Absa Herbals, Chennai  Active Ingredient  
Bacopa monnieri 
 
Absa Herbals, Chennai  Active Ingredient  
Lippia nodiflora 
 
Absa Herbals, Chennai  Active Ingredient  
Oldenlandia heyneii 
 
Absa Herbals, Chennai  Active Ingredient  
Allium sativam 
 
Absa Herbals, Chennai  Active Ingredient  
Smilax zylanica, 
 
Absa Herbals, Chennai  Active Ingredient  
Talc New drugs and chemicals,  
Bangalore  
Excipient 
Dicalcium phosphate 
 
Global medicines ltd, Gujarat  Excipient 
Aerosil 
 
Global medicines ltd, Gujarat  Excipient 
Magnesium stearate 
 
Global medicines ltd, Gujarat  Excipient 
Sodium methyl paraben 
 
Global medicines ltd, Gujarat  Preservative 
Sodium benzoate 
 
Global medicines ltd, Gujarat  Preservative 
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EQUIPMENTS USED FOR THE STUDY 
  
The equipments/instruments used in the study were as follows:  
 
                  Table 7.2 Equipments used for the study  
 
 
S.NO 
 
Name of the Equipments  
 
 
Manufacturer/suppliers  
 
1 
 
Weighing balance  
 
 
Shimadzu, Japan  
 
2 
 
Hot air oven  
 
 
Industrial Heaters, Chennai  
 
3 
 
Muffle Furnace  
 
 
Industrial Heaters, Chennai  
 
4 
 
Disintegration Test 
apparatus  
 
 
Veego, Mumbai  
 
5 
 
Blender  
 
 
Cadmach, Mumbai  
 
6 
 
Capsule filling machine 
 
 
Pam Pharma and Allied 
Machinery Co.Pvt.Ltd 
 
7 
 
Digital pH meter  
 
 
Symchrony, India  
 
8 
 
Soxhlet apparatus  
 
 
Symchrony, India  
9 
 
Stability chamber  
 
 
Technico india, Mumbai  
 
10 
 
UV spectrophotometer  
 
 
Shimadzu, Japan  
 
11 
 
Atomic Absorbance  
Spectrophotometer (6300)  
 
 
 
Shimadzu, Japan  
 
 
 
7.1.1 ANALYSIS OF RAW MATERIALS:  
 
Sampling of the raw materials.
52
 
  
             From each container or package selected, three original samples were taken with care to 
avoid fragmentation. Samples were taken from the top, middle and bottom of the container. In 
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the case of sacks and packages, the three samples were taken by hand, the first from a depth of 
not less than 10 cm from the top and the second and third from the middle and bottom after 
cutting into the side of the package. The three original samples were then combined into a pooled 
sample which was mixed carefully. The average sample was obtained by quartering the pooled 
sample. 
 
Authentication using reference samples 
              The original samples taken were authenticated by comparing with the authentic samples 
of the raw materials. 
 
7.1.2 FOR CRUDE HERBAL DRUGS
53
 
 
            For crude herbal drugs, determination of foreign organic matter, loss on drying, total ash, 
acid insoluble ash, water soluble ash, sulphated ash, water soluble extractive, alcohol soluble 
extractive, limit tests for heavy metals, microbial load analysis were analysed according to 
Ayurvedic Pharmacopoeial procedure. 
Determination of foreign matter 
             100g of the drug sample was weighed and then it was spread out in a thin layer. The 
foreign matter was detected by inspection with the use of a lens. Foreign matter found were 
separated and weighed and the percentage was calculated. 
    Foreign organic matter = Weight of the sample after inspection 
                                             Weight of the sample before inspection 
Determination of moisture content 
      The loss on drying test is important when the herbal substance are known to be 
hygroscopic. An excess of water in medicinal plant materials will encourage microbial growth, 
the presence of fungi, insects and deterioration. In modern pharmaceutical technology, the water 
content provides information concerning the shelf life and quality of the drugs. 
           About 10 g of the drug (without preliminary drying) was placed after accurately weighed 
(within 0.01g) in a tarred evaporating dish and dried at 105
о
c for 5 hours and weighed. The 
drying was continued and weighed, until the difference between two successive weighings 
corresponds to not more than 0.25 % at one hour interval. Constant weight is reached when two 
                                                                             MATERIALS AND METHODS 
 
Dept. of Pharmacognosy, COP, MMC Page 33 
 
consecutive   weighings after drying for 30 minutes and cooling for 30 minutes in a desicator 
show not more than 0.01 g difference. 
               Moisture content (%) = Final weight of the sample ×100 
                                                     Initial weight of the sample 
 
 
DETERMINATION OF ASH VALUE 
            Ash values of a crude drug is defined as the inorganic residue remaining after 
incineration, which simply represent inorganic salts, naturally occurring in drug or adhering to it 
or deliberately added to it as a form of adulteration. Hence the ash values are helpful in 
determining the quality and purity of the crude drug in the powdered form.  
Determination of Total ash value  
           About 2 grams of sample was weighed in a tared platinum or silica dish and was 
incinerated at a temperature not exceeding 450
о
c until the sample free from carbon, cooled and 
weighed. The ash obtained was weighed. The percentage of the total ash was calculated. 
                      Total ash value = Weight of residue obtained ×100 
                                                   Weight of the sample taken 
 
 
Determination of acid insoluble ash value 
    The total ash was boiled with 25 ml of dilute hydrochloric acid for 5 minutes, insoluble matter 
was collected on an ashless filter paper, washed with hot water and ignited, cooled in desiccators 
and weighed. The percentage of acid insoluble ash was calculated. 
                   Acid insoluble ash = Weight of residue obtained ×100 
                                                     Weight of the sample taken 
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Determination of water soluble ash value 
        The water soluble ash obtained from the total ash was boiled for 5 minutes with 25 ml of 
distilled water insoluble matter was collected in an ashless filter paper, washed with hot water, 
and ignited for 15 minutes at a temperature not exceeding 450 
о
c. The percentage of water 
soluble ash was calculated.  
                 Water soluble ash = Weight of residue obtained ×100 
                                                  Weight of the sample taken 
 
Determination of sulphated ash value 
          Silica crucible was heated to redness for 10 minutes, allowed to cool in a desiccator and 
weighed. 2g of the substance, accurately weighed, in to the crucible, ignited gently at first, until 
the substance is thoroughly charred. Cool, moisten the residue with 1 ml of sulphuric acid, 
heated gently until white fumes are no longer evolved and ignite at 800
 о
c± 25
 о
c until all black 
particles have disappeared. The ignition was conducted in a place protected from air currents. 
The crucible was allowed to cool, add a few drops of  sulphuric acid heat. Ignite as before, cool 
and weighed . 
                    Sulphated ash = Weight of residue obtained ×100 
                                               Weight of the sample taken 
 
EXTRACTIVE VALUES   
            The extractive values obtained by exhausting the crude drugs with solvent are indicative 
of the approximate measure of their chemical constituents. Taking into consideration the 
diversity in chemical nature and properties of contents of drugs, various solvents used for 
determination of extractive values. 
Determination of water soluble extractive value      
   5 g of the air dried coarsely powdered drug was macerated with 100 ml of ethanol (95%) in a 
closed flask for 24 hours, shaking frequently (or in a mechanical shaker) during 6 hours and 
allowed to stand for 18 hours. Rapidly filtered, taking precautions against loss of solvent, 
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evaporated 25 ml of the filtrate to dryness in a tarred flat bottomed shallow dish and dried at 
105
о
c to constant weight and weighed. The percentage of water soluble extractive was 
calculated. 
Water soluble extractive value = Weight of the dried extract × 100 
                                                     Weight of the sample taken 
 
Determination of alcohol soluble extractive value 
         Procedure for water soluble extractive was followed for the determination of alcohol 
soluble extractive but the solvent used is 90% ethanol instead of alcohol. 
                 Water soluble extractive value = Weight of the dried extract × 100 
                                                                      Weight of the sample taken 
 
 Determination of Crude fibre content 
               The crude raw material should be powdered and mixed thoroughly. About 2 gm (it 
should be in between 2 to 2.1 gm) of the powdered sample must be weighed accurately and taken 
in 250 ml of dil. Sulphuric acid solution in a long necked 500 ml beaker. Then the beaker is 
placed in a hot plate and a flat bottomed round flask with long neck containing distilled water is 
placed above the beaker in order to condense the vapours (Note: Should be take care that the 1st 
appearance of the first bubble, after that boil for half an hour).Then filter by using a clean cloth 
and wash the precipitate with hot water to remove the acid, then collect the precipitate by 
washing with the dilute sodium hydroxide solution in a long neck beaker. Then collect the 
precipitate by filtering in a clean cloth .Then take carefully all the precipitate and transfer it into 
a silica crucible. Dry it in hot air oven for 6-8 hours and then cool. Weighed and kept in muffle 
furnace for half an hour, cool and then weighed.  
 
 PRELIMINARY PHYTOCHEMICAL SCREENING 
54
  
            The crude raw material was subjected to preliminary phytochemical tests as per 
Phytochemical Methods. 
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Alkaloids: 
             To the extract, added few drops of bismuth iodide solution (dragendorff’s reagent), 
reddish brown color was observed, which indicates the presence of alkaloids. 
Carbohydrates: 
              In a test tube containing ethanolic extract of powdered drug, added 2 ml of distilled 
water and 2 drops of freshly prepared 20% alcoholic solution of alpha napthol. Mixed well and 
added 2 ml of concentrated sulphuric acid along the side of the test tube. Formation of red violet 
ring was observed at the junction of two layers, which disappears on addition of excess alkali 
solution, which confirms the presence of carbohydrates. 
Glycosides: 
              Extracted 200 mg of drug with 5 ml dil sulphuric acid by warming on a water bath, 
filtered it and neutralized the acid extract with 5% solution of sodium hydroxide. Added 1 ml of 
fehlings’s solution A and B until it became alkaline and heated on a water bath for 2 mins. 
Formation of red precipitate was observed, which indicates the presence of glycosides. 
Phenols:  
             Dissolved a small quantity of ethanolic extract of the drug with 2 ml of distilled water, 
added a few drops 10% aqueous ferric chloride solution. A blue or green color was produced, 
which indicates presence of phenols. 
Proteins (Biuret’s test) 
             To 1 ml of ethanolic extract of the drug, 5 to 8 drops of copper sulphate solution (10%) 
was added. Formation of violet color was observed, which indicates the presence of proteins. 
Saponins 
            To 5 ml of ethanolic extract of the drug, added a few drops of sodium bicarbonates 
solution. Shake the mixture vigorously and left for 3 minutes. Honey comb like froth developed, 
which indicates the presence of saponins. 
Tannins  
            The substance was mixed with basic lead acetate solution formation of white precipitate 
was observed, which indicate presence of tannins. 
Steroids   
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                Treated the extract with few drops of acetic anhydride, boiled and cooled, and added 
concentrated sulphuric acid from the side of the test tube. A brown ring was formed at the 
junction two layers and upper layer turns green, which shows presence of steroids. 
Flavones (shinoda test) 
                To the extract in alcohol few magnesium turnings and few drops of concentrated 
hydrochloric acid were added and boiled for 5 minutes and red coloration was observed, which 
shows for the presence of flavones. 
Triterpenoids  
               Treated the extract with few drops of con.sulphuric acid , formation of yellow color 
was observed, which shows the presence of triterpenoids. 
 
FLUORESCENCE ANALYSIS 
55
 
            Samples were studied for any color changes with different chemicals and solvents. The 
samples were observed under UV chamber in different wavelengths viz., 254 nm (short 
wavelength) , ordinary light and 366 nm.(long wavelength).  
 
HEAVY METALS ANALYSIS 
56
 
  
    The formulation was analyzed for its heavy metals limits.  
 
        Preparation of samples and standards by acid digestion method 
  
            Accurately weighed 2 g of sample was taken in Kjeldahl flask. Acid mixture of 
HNO3:HClO4 (4:1) was added in the flask and heated continuously till the solution was 
colourless. The sample was then transferred in a 25 ml volumetric flask and the volume was 
made-up with distilled water. Reagent blank was synchronously prepared according to the above 
procedure. The standards of Lead (Pb), Arsenic (As) and mercury (Hg) were prepared as per the 
protocol and the calibration curve was developed for each of them. Then samples were analyzed 
for the presence of Lead, Arsenic and mercury using Atomic Absorbance Spectrophotometer 
(AAS) (6300 SHIMADZU). 
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MICROBIAL LOAD ANALYSIS: 
          The following test are carried out for the estimation of number of viable aerobic 
microorganisms present and for detecting the presence of designated microbial species in the 
herbal medicines. 
1. Total aerobic viable count 
2. Yeast and moulds 
3. Escherichia coli 
4. Salmonellae 
5. Shigella 
6. Streptococcus  
7.2 PREFORMULATION STUDIES
57
 
              Prior to the development of the major dosage forms, it is essential that fundamental 
Physical and chemical properties of the drug molecule and other derived properties of the drug 
Powders are determined. This information decides many of the subsequent events and 
approaches in formulation development. This first learning phase is known as Preformulation.  
 
Definition:  
               Preformulation involves the application of biopharmaceutical principles to the 
Physicochemical parameters of drug substance are characterized with the goal of designing 
Optimum drug delivery system. Before beginning the Preformulation programs the 
Preformulation scientist must consider the following factors:  
 The amount of drug available.  
 The physicochemical properties of the drug already known.  
 Therapeutic category and anticipated dose of compound.  
 The nature of information, a formulation should have or would like to 
have.  
7.2.1 DETERMINATION OF THE GRANULES PARAMETERS
58
 
 Bulk density  
 Tapped density  
 Compressibility index  
 Hausner’s ratio  
 Angle of repose  
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Bulk density (ρb)  
                 It is determined by measuring the volume of a known mass of powder sample that has 
been passed through a screen into a graduated cylinder or through a volume measuring apparatus 
into a cup. It is expressed in g/ml and is given by,  
                                                 ρb = M/Vo  
 
                     Where, M - is the mass of powder  
                                  Vo- is the bulk volume of the powder.  
               The inter particle interactions that influence the bulking properties of a powder are also 
the interactions that interfere with powder flow, a comparison of the bulk and tapped densities 
can give a measure of the relative importance of these interactions in a given powder. Such a 
comparison is often used as an index of the ability of the powder to flow. 
  
Tapped density (ρt)  
 
               It is achieved by mechanically tapping a measuring cylinder containing a powder 
sample. After observing the initial volume, the cylinder is mechanically tapped and volume 
readings are taken until little further volume change is observed.  
              The mechanical tapping is achieved by raising the cylinder and allowing it to drop under 
its own weight at a specific distance.  
             The tapped volume was measured by tapping the powder to constant volume. It is 
expressed in g/ml and is given  
 
                                               ρt = M/Vt 
 Where, M - Mass of powder and Vt- Tapped volume of the powder.  
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Compressibility index: (CI)  
 
                Compressibility is the ability of powder to decrease in volume under pressure. 
Compressibility is a measure that obtained from density determination. Weighed quantity of  
granules was transferred to 50 ml graduated cylinder, volume occupied by granules was noted 
down. Then cylinder was subjected to 500/ 750 and 1250 taps. The difference between two tabs 
should be less than 2%. The percentage Compressibility Index is calculated by using formula. 
  
                                                CI = Vo-Vi ×100 
                                                            Vo 
  
Where, Vo- Untapped density;     Vi- Tapped density  
 
Hausner’s Ratio 
                 It is measurement of frictional resistance of the granular material. The Ideal range 
should be 1.2 -1.5, it was determined by the ratio of tapped density and bulk density.  
 
                                            Hausner’s Ratio = Vi / Vo  
Where, Vo -Untapped density,  Vi -Tapped density 
  
Angle of repose 
               The tangent of angle of repose is equal to the coefficient of friction between the 
particles. Hence the rougher and more irregular the surface of particles, the greater will be angle 
of repose. For determination of angle of repose (Ɵ), the blends were poured through the walls of 
a funnel which was fixed at a position such that its lower tip was at a height of exactly 2.0 cm 
above a hard surface. The drug or the blends were poured till the time when upper tip of the pile 
surface touched the lower tip of the funnel. Angle of repose was calculated using following 
equation.  
The angle of repose Ɵ was calculated by the formula,  
                                           Tan Ɵ = h/r,  
                                             Ɵ = tan-1 (h/r)  
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            Where, Ɵ - angle of repose,  h- height in cm and  r- radius in cm.  
Based on the Angle of repose, Compressibility index and Hausner’s ratio, the flow property of 
the granules can be characterized. 
            Table 7.3 Angle of Repose, Compressibility Index and Hausner’s Ratio59 
Flow property Angle of repose Compressibility index Hausner’s ratio 
Exacellent 25-30 <10 1.00-1.11 
Good 31-35 11-15 1.12-1.18 
Fair 36-40 16-20 1.19-1.25 
Passable 41-45 21-25 1.26-1.34 
poor 46-55 26-31 1.35-1.45 
Very poor 56-65 32-37 1.46-1.59 
Very very poor >66 >38 >1.60 
 
 
FORMULATION DEVELOPMENT STUDIES  
7.2.2 SELECTION OF EXCIPIENTS
60
 
 
                 For the formulation of capsules in addition to the active ingredients, excipients like 
diluents (filler), binder, disintegrating agent, lubricant and preservatives are required. The choice 
of excipients was made keeping in mind the current Food and Drugs Administration (FDA) 
regulations. 
  
Diluents: Diluents/Fillers are added where the quantity of active ingredient is less (or) difficult 
to filling. Common tablet/capsule filler include Lactose, Dicalcium phosphate, Microcrystalline 
cellulose, etc. 
  
Lubricants: They reduce friction during the filling process. In addition, they aid in preventing 
adherence of capsule material. Magnesium Stearate, Stearic acid, Hydrogenised vegetable oils 
and talc are commonly used lubricants. 
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Glidant: It is used to improve flow of the powder materials by reducing the friction between the 
particles. The most effective glidants are the Colloidal silicon dioxide, Talc and Starch. 
  
Preservatives: The preservatives are added to herbal formulation to prevent contamination, 
deterioration and spoilage by bacteria, fungal and other microorganisms. The most effective 
preservatives are the sodium methyl paraben, sodium propyl paraben, sodium benzoate and 
bronopol.  
 
EXCIPIENTS USED:  
 
DILUENTS / FILLERS : Starch, Lactose, Magnesium stearate.  
        GLIDANTS                      : Talc, colloidal silicon dioxide, starch 
PRESERVATIVES         :  Sodium methyl paraben, Sodium benzoate  
 
 
GRANULATION 
61
 
                Granulation is defined as a process of size enlargement, widely used in pharmaceutical,  
food, chemical, agriculture, animal feed and other industries in which powder particles are made  
to form larger, multi particle entities called granules. Pharmaceutical granules typically have a 
Size range between 0.2-0.4 mm, depending on their subsequent use. It is one of the most 
important unit operations for powder handling in pharmaceutical industry. The appearance, 
elegance and ease of filling of capsules are dependent on variety of variables like materials used, 
processing techniques and equipment used for ultimate quality of granules produced. 
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      Table 7.4  Formula for granule preparation  
ACTIVE 
INGREDIENTS 
QUANTITY 
mg/ capsule 
Asparagus racemosus 20mg 
Bacopa monnieri 1.5mg 
Lippia nodiflora 110mg 
Oldenlandia heyneii 100mg 
Allium sativam 15mg 
Smilax zeylanica 100mg 
 
             
 PREPARATION OF GRANULES: 
  
            Step 1: All the individual herb plant materials were cleaned and then washed with 
demineralized water for 3-4 times and dry with shade.  
 
           Step 2: Each dried plant material was pulverized and passed through sieve 30 slotted 
stainless steel mesh. 
  
           Step 3: Plant ingredients weighed individually and pulverized into a moderately fine 
powder in a stainless steel pulveriser then mixed along with the binder and other excipients. To 
get uniform mixing. 
  
           Step 4: After, QA approval the granules were filled in “0” size red capsule with average  
content weight at 520mg.  
 
 
 
SCHEME: POLYHERBAL CAPSULE FORMULATION  
 
                    Formulation Development of polyherbal Capsules:  
 
 
                                      Active materials +  Inactive materials  
 
 
 
                                                              Sifting  
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                                                              Mixing  
                                                  
                                                                
 
 
Blend (Evaluation of Bulk density, Tapped density, Angle of repose, Compressibility Index, 
Hausner’s ratio) 
 
                                                                   
 
                                               Capsule filling (Uniformity of weight, DisintegrationTest)  
 
7.3 Trial batches: (Size: 500 Capsules)  
 
             Various trial batches (size: 500 capsules) were formulated by varying the composition of 
the excipients proportions. Based on the various excipients proportions five trial batches given in 
Table 7.5  
                               Table7.5 Trial batches (Size: 500 capsules)  
 
Materials Trial- 1 Trial- 2 Trial- 3 Trial- 4 Trail- 5 
 
Asparagus racemosus 20 mg 20 mg 20 mg 20 mg 20 mg 
Lippia nodiflora 110 mg 110 mg 110 mg 110 mg 110 mg 
Olden landia heynaii 100 mg 100 mg 100mg 100 mg 100 mg 
Smilax zylanica 100 mg 100 mg 100 mg 100 mg 100 mg 
Allium sativam 15 mg 15 mg 15 mg 15 mg 15 mg 
Bacpa monnieri 1.5 mg 1.5 mg 1.5 mg 1.5 mg 1.5 mg 
Talc 100 mg - 100 mg 100 mg 100 mg 
Aerosil 1 mg 1mg - 1 mg 1 mg 
Dicalcium phasphate - 100 mg 50 mg 50 mg 50 mg 
Magnesium sterate - - 2 mg - 1.25 mg 
Sodium Methyl Paraben 0.5 mg 0.5 mg 0.5 mg 0.5 mg 0.5 mg  
Sodium benzoate 0.5 mg 0.5 mg 0.5 mg 0.5 mg 0.5 mg 
  
From the above trial batches, the trial batch 5
th
 trial was found to be the perfect batch and it was 
selected for the consideration of further large scale manufacturing. 
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FINAL TRIAL BATCH SIZE: 5000 CAPSULES: 
 
Table7.6 Final trial batch (Size: 5000 Capsules)   
 
                             
                                                                
  
                                                                                                  Fig.7.1 Formulated capsules 
 
 
 
CAPSULE FILLING  
 
 The formulated granules were filled in “0” size capsules to an average net content                           
         weight of 520 mg.  
  
 The capsules were then dedusted, transferred into polybags, labelled and the samples  
                    were evaluated as per the testing requirements.  
  
 After approval from QAD the capsules were packed as per the packing instructions. 
   
 From the final trial, samples were taken for accelerated stability studies as per the  
                    Testing requirements.  
 
 
7.4 STANDARDISATION OF FINISHED PRODUCT
62,63
 
  
          The developed capsules were subjected to following studies for their standardization:  
 
 Evaluation of capsules  
S.NO Ingredient Quantity 
(mg/capsules) 
1 Asparagus racemosus 20 mg 
2 Lippia nodiflora 110 mg 
3 Olden landia heynaii 100 mg 
4 Smilax zylanica 100 mg 
5 Allium racemosus 15 mg 
6 Bacopa monnieri 1.5 mg 
7 Talc 100 mg 
8 Aerosil 1 mg 
9 Dicalcium phasphate 50 mg 
10 Magnesium sterate 1.25 mg 
11 Sodium Methyl Paraben 0.5 mg 
12 Sodium benzoate 0.5 mg 
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 Physicochemical parameters  
 Phytochemical studies  
 Heavy metal analysis  
 Microbial load analysis  
 
 
7.4.1 EVALUATION OF CAPSULES  
 
 Description  
 Uniformity of weight  
 Disintegration test  
 Moisture content  
 
 Description 
  
            The general appearance of a capsule, its visual identity and overall “elegance” is essential 
for consumer acceptance. The color, shape, odor and surface texture are all noted for the capsules 
prepared. 
 
Uniformity of weight  
 
             20 individual units were selected at random and their content was weighed and their  
Average weight was calculated. Not more than two of the individual weights deviate from the 
average weight by more than the percentage shown in the table 7.7 
  
                                Table: 7.7 Acceptance Criteria I.P Limit 
 
 
 
 
 
 
 
 
  
Dosage form Average weight 
 
% Deviation 
Capsules <300 mg 
 
10 % 
>300 mg 
 
7.5 % 
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Disintegration test  
 
                     This test was done to measure the time taken by the formulation to disintegrate in a 
liquid medium. This is done to determine whether the capsule disintegrates within the prescribed 
time when placed in a liquid medium under the prescribed experimental conditions. One capsule 
each was added to each of the six tubes of the basket and a disc was added to each of the tube. 
The tubes were dipped in 0.1N HCl solution maintained at 37°C. The time was noted.  
 
 
Determination of moisture content  
 
                The method was carried out as detailed in the 7.1.2 in this chapter given earlier. 
 
 
7.4.2 PHYSICOCHEMICAL PARAMETERS 
 
P
H
  
         1 g of capsule powder was taken and dissolved in 100 ml demineralized water. The pH 
value of the solution was determined by means of a digital P
H
 meter. The pH meter was 
calibrated using buffers of 4, 9 and 7 P
H
. The electrodes were immersed in the test solution and 
P
H
 was measured. 
 
FOR POLYHERBAL FORMULATION 
  
        Determination of Foreign organic matter, Loss on drying, Total ash, Acid insoluble ash, 
Water soluble ash, Sulphated ash, Water soluble extractive, Alcohol soluble extractive, 
Microbial load analysis were analysed according to Ayurvedic Pharmacopoeial procedure. 
 
CRUDE FIBRE CONTENT  
  
           The determination of crude fibre content was carried out as detailed in the 7.1.2 in this 
chapter earlier.  
 
7.4.3 PHYTOCHEMICAL STUDIES 
 
 Preliminary Phytochemical examination 
  
            The preliminary phytochemical examination was carried out as detailed in the 7.1.2 in 
this chapter given earlier.  
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7.4.4 QUANTITATIVE ESTIMATION OF PHYTOCHEMICALS 
  
 Quantitative Estimation of Total Alkaloids
64
 
                 5 g of the granules were weighed into a 250 ml beaker and 200 ml of 10 % Acetic acid  
in ethanol was added, covered and allowed to stand for 4 h. This was filtered and the extract was 
concentrated on a water bath to 1/4th of the original volume. Concentrated NH4OH was added 
drop wise to the extract until the precipitation was completed. The whole solution was allowed to 
settle and the precipitate was collected and washed with dilute NH4OH and then filtered. The 
residue was dried and weighed. 
 
Quantitative Estimation of Total Saponins  
                    20 g of the granules were weighed and 100 ml of 20 % Ethanol was added. Then the  
sample was heated over a hot water bath for 4 hours with continuous stirring at about 55º C. The 
mixture was filtered and the residue re-extracted with another 200 ml 20 % ethanol. The 
combined extract was reduced to 40 ml over water bath at about 90º C. The concentrate was 
treated with 20 ml of diethyl ether and the aqueous layer was recovered while the ether layer was 
discarded. This process of purification was repeated three times and then 60 ml of n- Butanol 
was added and extracted. The n-Butanol extract obtained was then washed two times with 10 ml 
of 5% Aqueous sodium chloride. The remaining solution was heated in a water bath for 
evaporating the solvent. After evaporation the samples were dried in the oven to a constant 
weight and the Saponin content was calculated as percentage.  
 
Quantitative estimation of Total Tannins
65
 
 
                 Tannin content present in the formulation was estimated by Tocklai-Lowenthal 
method. This is basically an Oxidimetric titration of the infusion of the sample followed by a 
similar determination on another portion from which tannin has been quantitatively removed. 
The difference between the “Total” and the “Non-Tan” titres gives the tannin titre. The infusion 
of the sample of extract was prepared by boiling 5 g sample with 400 ml water for 1 hour, 
cooling and making up the volume of the extract to 500 ml. The separation into tannins and non-
tans was effected by gelatin. The following reagents were used.  
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1. Gelatin solution:  
 
           25 g gelatin was soaked for 1 hour in Saturated Sodium chloride solution. The mixture 
was then warmed until the gelatin got dissolved and after cooling the solution was made up to 
1litre with Saturated Sodium chloride. 
2. Acid Sodium chloride:  
 
           25 ml of conc. Sulphuric acid was added to 975 ml Saturated Sodium chloride solution. 
100 ml of the sample infusion was mixed with 50 ml of the gelatin solution, 100 ml of acid 
Sodium chloride and 20 g of powdered Kaolin. After shaking for several minutes and allowing 
settling, the mixture was filtered and an aliquot of the filtrate withdrawn for titration. 25 ml of 
the non-tan filtrate is equivalent to 10 ml of the original infusion. 
 
The Tocklai - Lowenthal method:  
 
    The following reagents were used: 
   (1) N/25 Potassium permanganate;  
   (2) 1-5 g Indigo carmine dissolved in 1litre water containing 50 ml Sulfuric acid.  
            A 10 ml aliquot of the infusion is mixed with 25 ml of the Indigo-carmine solution and 
the mixture diluted to 750 ml Potassium permanganate was then run in from a burette 1 ml at a 
time with brisk shaking. As the titration proceeded, the blue of the Indigo-carmine passed 
through many shades to a final yellow with a faint pink tint at the rim. This was taken as the 
endpoint.  
(Note: This needs considerable judgement on the part of the operator. The titre is affected to 
some extent by the amount of tannin in solution, the time taken in the titration and the vigor of 
shaking. Repeats often differ by 0-3 ml or more and the variation between different operators 
may amount to 1 ml.) The tannin titre was arrived at by subtracting the non-tan from the total 
titre. The equivalent weight factor is 0.0416. 
 
Quantitative estimation of total flavonoids
66
 
 
             10g of the sample was extracted repeatedly with 100ml of 80% Aqueous Methanol at 
room temperature. The whole solution was filtered through Whatman filter paper No.42 
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(125mm). The filtrate was later transferred into a crucible and evaporated into dryness over a 
water bath and weighed to a constant weight. 
 
7.4.5 CHROMATOGRAPHIC FINGERPRINTING OF HERBAL PRODUCTS 
67
 
 
              Chromatographic fingerprinting has been in use for a long time for single chemical 
entity drug substances. Recently it has become one of the most powerful tools for quality control 
of herbal medicines. The use of chromatographic fingerprinting for herbal drugs tends to focus 
on identification and assessment of the stability of the chemical constituents observed by various 
chromatography techniques such as HPLC, TLC, HPTLC, GC, capillary electrophoresis. 
 
 
HPTLC Finger printing of polyherbal capsules: 
 Chromatographic conditions: 
Instrument   : CAMAG HPTLC 
HPTLC Applicator  : CAMAG LINOMAT IV  
HPTLC Scanner  : CAMAG TLC SCANNER II 
Method    : as per AHRF Method  
Mobile phase   : Ethyl acetate: Hexane (6:4) 
Stationary phase  : HPTLC Silica MERCK 60F 254  
Sample dilution  : 10 mg of sample dissolved in 1 ml of ethyl acetate  
Vol. Of sample loaded  : 20 μl  
Lambda max   : 254 nm  
Detection   : Rf value was calculated, peak area of each band was detected. 
 
 
7.4.6 HEAVY METALS ANALYSIS
67
 
  
            The formulation was analyzed for its heavy metals limits. Discussed earlier (7.1.2)  
 
 
7.4.7 DETERMINATION OF PESTICIDAL RESIDUE BY TLC
68
 
 
             Pesticide residues generally accumulate from agricultural practices of spraying, treating 
soils during cultivation and through the administration of fumigants during storage. Since many 
medicinal preparations of plant origin are taken over long periods of time, limits for pesticide 
residues should be established, following recommendations of the Food and Agriculture 
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Organization (FAO) of the United Nations and World Health Organization (WHO) which have 
already established the safety index of these residues in food and animal feed. These guidelines 
include the analytical methodology of Pesticidal residues. Out of various pesticides available, 
only chlorinated hydrocarbons and related pesticides like aldrin, BHC, Chlordane, Dieldrin, 
DDT and a few Organo-phosphorus pesticides like Carbophenothion retain a long residual 
action.  
 
Extraction of common pesticide from material:  
 
          10 g of polyherbal capsule powder were taken in a round bottom flask and added Sodium 
sulfide with 100ml n-Hexane. It was refluxed for 1 hour and filtered. The filtrate extracted with 
50ml and 25ml of Acetonitrile. The Acetonitrile layer was mixed with 500ml demineralized 
water with 2.5ml saturated sodium sulfide and then extracted with an n-Hexane layer and 
evaporated on a water bath. This residue was used for the analysis of Organochloro, 
Organophosphate and Carbamate pesticides by Thin layer chromatography using standard 
reference compounds (Accu standards, USA). 
 
TLC details:  
 
  Sample solution           : Residue in Methanol  
  Development system   : Benzene : Methanol (60: 40)  
  Stationary Phase          : Silica gel 60 F254 TLC plate of 0.2mm thickness.  
  Detection                     : By UV Absorption Range from 200 to 300nm.  
          The Extracts were spotted along with reference standards and chromatogram was 
developed and analyzed under UV from 200 to 300 nm.  
 
7.5 ACCELERATED STABILITY STUDIES OF CAPSULES
69,70,71,72
 
 
Definition  
                 Stability is defined as the extent to which a product retains, within specified limits and  
throughout its period of storage and use (i.e., its shelf-life), the same properties and 
characteristics that it possessed at the time of its manufacture.  
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Essential conditions for stability studies:  
 
    The stability study shall be performed for the following conditions:  
 Introduction of new products/new process.  
 Change in the manufacturing process/critical process parameter.  
 Change in vendor of an active raw material, Change in facility/location.  
 Reprocessing for the first time.  
 Change in the packaging mode/new packs.  
 For regulatory purposes.  
 Change in the storage condition.  
 
Conditions of Stability studies  
 
            Accelerated condition of 40° C ± 2° C / 75% RH ± 5% RH  
 
 Long term condition of 25° C ± 2° C / 60% RH ± 5 % RH  
 Long term / intermediate condition of 30° C ± 2° C / 75 % RH ± 5% RH  
 
The ICH Harmonized Tripartite Guideline provides a general indication on the requirements for 
stability testing of new drug substances and products. The main thrust of the stability guideline 
centers on criteria for setting up stability protocols.  
Climatic zones: The four zones in the world that are distinguished by their characteristic  
                            prevalent annual climatic conditions.  
Table: 7.8  Climatic zones and derived storage conditions (± 2°C / ± 5% RH)  
 
 
 
 
 
 
 
 
    
 
 
   
       As our country comes under zone IV, the following conditions were maintained throughout 
the study  
Zone  Condition  Temperature  Humidity 
  
Zone I  Temperate  21°C  
 
45% RH  
Zone II  Subtropical, with possible high 
humidity  
25°C  60% RH  
Zone III  Hot/dry  30°C  
 
35% RH  
Zone IV  Hot/humid  40°C  
 
70%RH  
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                       Table:7.9 Accelerated stability condition  
Study Storage condition Time period covered 
Accelerated stability study 40°C ±2°c 3months 
 
  
   The stability study of capsules under accelerated conditions was done according to the  
ICH guidelines and the duration of study were 6 months. The conditions of temperature and 
relative humidity were maintained 40° C ± 2° C / 75% RH ± 5% RH respectively in the stability 
chamber.  
THE PARAMETERS STUDIED WERE:  
 
 Description  
 Uniformity of weight  
 Disintegration test  
 Moisture content  
 pH  
 Total ash  
 Acid insoluble ash  
 Water soluble ash  
 Sulphated ash  
 Water soluble extractive  
 Alcohol soluble extractive  
 Crude fibre content  
 Quantitative estimation of Total Alkaloids  
 Quantitative estimation of Total Saponins  
 Quantitative estimation of Total Flavanoids  
 Quantitative estimation of Total Tannins  
 Microbial load analysis  
          Total aerobic bacteria  
          Yeasts and Moulds  
          Escherichia coli  
          Salmonella  
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          Shigella  
                             Streptococcus  
 
                      The samples were analyzed for all the parameters except microbial load 
analysis at the beginning of the study and at the end of 30 day, 60 days and 90 days. 
 
PHARMACOLOGICAL EVALUATION  
Preparation of extract:  
               Polyherbal capsule powders were successfully extracted with hydro alcoholic mixture 
(3:2) for 10hrs using soxhlet method. Then the hydro alcoholic extract was centrifuged twice at 
1500rpm for 5 min. Then the extract was subjected to evaporation on water bath to dryness. The 
resulted dried extract was used for the in vitro antioxidant and antiarthritic activity. 
  
7.6 IN VITRO ANTIARTHRITIC ACTIVITY
73,74,75,76
 
7.6.1 INHIBITION OF PROTEINASE ENZYME ACTIVITY 
Principle  
                Neutrophils are known to be a rich source of proteinase. They carry many neutral 
serine Proteinase in their lysosomal granules. It was previously reported that leucocyte 
proteinase play an important role in the development of tissue damage during inflammatory 
reactions. Trypsin is a serine protease found in the digestive system of many vertebrates, where it 
hydrolyses proteins. In this assay trypsin is used as protease enzyme and casein is used as 
substrate.  
Requirements 
 Trypsin  
 25mM Tris HCl buffer (PH 7.4)  
 0.8%w/v Casein  
 70% v/v Perchloric acid  
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Procedure  
 The reaction mixture (2.0 ml) contains 0.06 mg trypsin, 1.0 ml of 25 mM Tris-HCl 
buffer (pH 7.4) and 1.0 ml Aqueous solution of test sample (100, 200, 400,800 mcg/ml) and 
were incubated at 37ºC for 5 minutes.  
 Then 1.0 ml of 0.8% (w/v) Casein was added and incubated for 20 minutes.  
 2.0 ml of 70% (v/v) Perchloric acid was added to terminate the reaction. The cloudy 
suspension was centrifuged.  
 Optical density of the supernatant was read at 280 nm against buffer as blank. The 
percentage of inhibition was calculated using the following formula.  
 
            Percentage inhibition = (O.D. of control –O.D. of sample) X100  
                                                              O.D. of control  
 
 
7.6.2 PROTEIN DENATURATION ASSAY  
Principle 
                Protein denaturation is a process in which proteins lose their tertiary structure and 
secondary structure by application of external stress or compound such as strong acid or base, a 
concentrated inorganic salt, an organic solvent or heat. Most biological proteins lose their 
biological function when denatured. Denaturation of proteins is a well-documented cause of 
inflammation in RA. In this assay the proteins denaturation was induced by heat.  
Requirements 
 5% Aqueous solution of Egg albumin  
  Phosphate buffer saline (PH 6.3)  
 1N HCl  
 
Procedure:  
 The reaction mixture (5ml) consists of 0.05ml of test sample (100, 
200,400,800mcg/ml) and 4.5ml egg albumin (5% aqueous solution), pH of the reaction mixture 
was adjusted at 6.3 using small amount of 1N HCl.  
 Then incubated at 37 ºC for 20 min and then heated to 51º C for 20 min. After cooling 
the samples, the turbidity was measured at 660nm.  
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 The experiment was performed in triplicate. The percentage inhibition of protein 
denaturation was calculated as follows 
                  Percentage inhibition = (O.D. of Control –O.D. Sample) X 100  
                                                                      O.D. of Control  
         Control represents 100% protein denaturation. The results were compared with standard  
(Diclofenac sodium 200 mcg/ml) sample.  
7.6.3 Membrane stabilizing assay  
 Principle 
              The erythrocyte membrane resembles to lysosomal membrane and as such the effect of 
drugs on the stabilization of erythrocyte could be extrapolated to the stabilization of lysosomal 
membrane. Therefore, as membrane stabilizes that interfere in the release or action of mediators 
like histamine, serotonin, prostaglandins, leukotrienes etc. The principle involved in this assay is 
stabilization of rat red blood cell membrane against hypo tonicity induced membrane lysis.  
Requirements  
  
  
  
Procedure  
 The reaction mixture (4.5 ml) consisted of 2 ml hypotonic saline (0.25% NaCl),1 ml 
0.15 M phosphate buffer (pH 7.4) and 1 ml test sample (100, 200, 400 and 800 mcg/ml of final 
volume) in normal saline. 0.5 ml of 10% rat RBC in normal saline was added.  
 For control sample, 1 ml of isotonic saline was used instead of test solution and 
sample solution without RBC act as product control.  
 The mixture was incubated at 56º C for 30 minutes. The tubes were cooled under 
running tap water for 20 minutes. The mixtures were centrifuged and the absorbance of the 
supernatant was read at 560 nm.  
Percentage membrane stabilizing activity was calculated as follows:   
 
Percentage Stabilization = 100- (O.D. of test – O.D. of Product control) x 100  
                                                                    O.D of Control  
The result was compared with standard (diclofenac sodium 200 mcg/ml) sample. 
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7.7 IN VITRO ANTIOXIDANT ACTIVITY
77,78,79
 
7.7.1 Reducing power assay   
Principle  
        The reducing properties are generally associated with the presence of reductones, which 
have been shown to exert antioxidant action by breaking the free radical chain by donating a 
hydrogen atom. Reductones are also reported to react with certain precursors of peroxide, thus  
preventing peroxide formation.  
Requirements:  
 Potassium ferricyanide  
 Phosphate buffer  
 Trichloroacetic acid  
 
Procedure  
              Assay of Reducing Power was carried out by potassium ferricyanide method. 2.5 ml of 
various concentrations of test sample were mixed with 2.5 ml phosphate buffer (0.2 M, pH 6.6) 
and 2.5 ml potassium ferricyanide [K3Fe (CN6)] (10g/L). The mixture was then incubated at 
50°C for 20 minutes. To this mixture 2.5 ml of trichloroacetic acid (100g/L) was added, which 
was then centrifuged at 3000 rpm for 10 minutes. Finally 2.5 ml of the supernatant solution was 
collected and mixed with 2.5 ml of distilled water and 0.5 ml Fecl3 (1g/L) and absorbance was 
measured at 700 nm. Ascorbic acid was used as standard and phosphate buffer as blank solution. 
Increased absorbance of the reaction mixture indicates stronger reducing power.  
 
               % Reductive ability = Absorbance of Control- Absorbance of Sample X100  
                                                                        Absorbance of Control  
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7.7.2 Nitric oxide radical scavenging assay 
Principle  
              Nitric oxide was generated from sodium nitroprusside which at physiological pH 
liberates nitric acid. This nitric acid gets converted to nitrous acid and further forms nitrite ions 
(NO2-) which diazotize with sulphanilic acid and couple with napthylethylenediamine (Griess 
reagent) producing pink colour which can be measured at 546 nm.  
Requirements: 
 Sodium nitroprusside  
 Griess reagent  
 
Procedure  
                  Nitric oxide was generated from sodium nitroprusside and measured by the Griess 
reaction. Sodium nitroprusside in aqueous solution at physiological pH spontaneously generates 
nitric oxide, which interacts with oxygen to produce nitric ions that can be estimated by use of 
Griess reagent. Scavenger of nitric oxide competes with oxygen leading to reduced production of 
nitric oxide. Sodium nitroprusside (5 M) in phosphate–buffered saline (PH 7.4) was mixed with 
3ml of various concentrations of polyherbal formulation and incubated at 25
º
C for 150 min. The 
samples from the above were reacted with Griess reagent. The absorbance of the chromophore 
formed during the diazotization of nitrite with Sulphanilamide and subsequent coupling with 
napthylethylenediamine was read at 546 nm. Ascorbic acid has taken as positive control.   
 
Nitric oxide Scavenging (%) = (Absorbance of Control - Absorbance of Sample) ×100  
                                                                  (Absorbance of Control)  
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7.8 IN VIVO ANTIARTHRITIC EVALUATION:  
 
ACUTE TOXICITY STUDY
80,81
 
          Acute toxicity study was designed as per the OECD guidelines 423. (Acute toxic class 
method).  
Principles and purposes 
               Acute toxicity testing determines the toxicity of a chemical or drug substances after 
single administration.  
                The main purpose of acute toxicity study is to evaluate the degree of toxicity in a 
quantitative and qualitative manner with the purpose of comparing it with other drug substances 
(e.g. other drug candidates for the same indication). Further acute toxicity testing provides 
information about the acute toxicity testing effects of a chemical in a quantitative manner i.e. it 
generate information about mechanism of acute toxicity.  
                The method of determination has changed in the last three decade mainly for animal 
welfare reasons producing mortality in animals in order to determine LD 50 is no longer the 
main purpose of acute toxicity testing. The test is based on stepwise procedure with use of 
minimum number of animals per step. Sufficient information is obtained on the acute toxicity of 
the substance to enable its classification. The substance is administered orally to a group of 
experimental animals at one of the defined dose. The substance is tested using a stepwise 
procedure, each step using three animals or a single sex (normally females). Absence or presence 
of compound related mortality of the animals dosed at one step will determine the next step i.e.  
 
     No further testing is needed  
     Dosing of three additional animals with the same dose  
     Dosing of three additional animals with the next higher (or) the next lower dose levels  
 
 Experimental animals:  
             Healthy adult non pregnant female wistar albino rats weighing between 150-200g were 
selected for the study. For all the three animals water was provided ad libitum and food was 
withheld overnight prior to dosing.  
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Selection of dose levels and administration of doses:  
          Being a traditional herbal medicine, the mortality was unlikely at the highest starting dose 
level (2000mg/kg body weight). Hence a limit test at one dose level of 2000mg/kg body weight 
was conducted in all the three animals.  
 
Observation:  
The animals were observed individually after dosing once during the first 30 minutes, 
periodically for the first 24 hours, with special attention given during the first 4 hours, and daily 
thereafter for a total of 14 days. The following clinical observation were made and recorded.  
 Toxic signs:  
                            All rats were observed for any toxic signs  
 Body weight:  
                            Individual body weight was recorded for all the animals.  
 Cage side observation:  
                            The faeces colour, faeces consistency, change in skin and fur, eyes, mucus 
membrane (nasal) of the animals were observed.  
 Physical Examination:  
                             Physical observation included changes in respiratory system (rate), 
cardiovascular system (heart rate), autonomic nervous system (salivation, lacrimation, 
piloerection, urinary incontinence and defecation), central nervous system (drowsiness, 
convulsions, motor activity, writhing, motor in coordination, righting reflex, pinna reflex, 
corneal reflex, tremors were recorded.  
 
7.9 IN VIVO EVALUATION OF ANTIARTHRITIC ACTIVITY 
82,83,84
 
            The protocol for conducting the in vivo study in female adult albino wistar rats was 
approved by the Institutional Ethical Committee (IEC) of the Madras Medical College, Chennai-
600003, India Approval no.vide 2/243/CPCSEA. Dated 22.11.13 
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Experimental design 
  
Induction of Arthritis : ( ) 
              Arthritis was induced by a single sub-planter injection of 0.1 ml of Complete Freund’s 
adjuvant (Sigma Chemicals, USA) containing 1.0 mg dry heat-killed Mycobacterium 
tuberculosis per milliliter sterile paraffin oil into a foot pad of the left hind paw of male albino 
wistar rats except vehicle control . The swelling in hind paws were periodically examined in each 
paw from the ankle using vernier caliper. Diclofenac sodium and Polyherbal capsules were 
administered orally in the form of freshly prepared Solution in distilled water.  
                                                                          
                                                               
                                                                        Fig7.2 After induction of CFA  
 
                       
Fig-7.3 Oral administration of test and standard drugs  
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The animals received the following treatments:  
       Group I: Distilled water, 1 ml/kg/day, orally for 14 days as Vehicle control.  
       Group II: Distilled water, 1ml/kg/day, orally for 14 days as Arthritic control  
       Group III: Diclofenac sodium,13.5mg/kg/day, orally for 14 days as Standard  
       Group IV: Polyherbal formulation 200 mg/kg/day, orally for 14days as Test drug I  
       Group V: Polyherbal formulation 400 mg/kg/day, orally for 14 days as Test drug II  
Measurement of paw swelling:  
       On 0th day, the left hind paw swelling of al rats was measured using vernier caliper and on 
1st day arthritis was induced in all rats using CFA. The aforementioned drug treatment was 
started on 1st day and continued for 14 days. The assessment of antiarthritic activity was carried 
out by measuring change in paw swelling and body weight on 4th, 8th, 14th and 21st day after 
induction. The percent inhibition of paw swelling as determined as:  
                                                   (VC-V0) – (Vt-V0) X100  
                                                                 (VC-V0)  
Where      VC is the paw swelling after induction,  
                V0 is the paw swelling before induction,  
                 Vt is the paw swelling after treatment.  
 
Estimation of Hematological parameters   
         On the 22nd day , blood was withdrawn through retro-orbital vein puncture of all groups and 
the biochemical parameters such as Hemoglobin content, Total WBC count, ESR, RBC, 
PCV,DC were analyzed.  
Radiographic study  
             Computer radiograph of arthritic induced Hock joint (ankle joint) and Stifle joints (knee 
joint) of treated and arthritic control group on 21st day were studied using Agfa CR Siemen 500 
MA X ray machine systems. The region between the distal femur and the proximal tibia 
(including patella) was radiographed through lateral views for study and interpretation.  
Histopathological examination   
            The animals were sacrificed by cervical dislocation and the ankle joints of hind limbs 
were removed and placed in 10% buffered formalin. The fixed tissues were then decalcified and 
the sections were stained with Hematoxylin and Eosin. Slides were reviewed for the evaluation 
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of histopathological changes like soft tissue swelling, bone demineralization, pannus formation, 
cartilage erosion and joint space narrowing.  
Statistical Analysis:  
            Results were expressed as Mean ± SEM. The data was analyzed using one way analysis 
of variance (ANOVA) followed by Dennett’s test. P values <0.01 were considered as Significant.  
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                                              8. RESULTS AND DISCUSSION 
8.1 ANALYSIS OF RAW MATERIALS  
Authentication:  
                    The raw materials used in the formulation were individually procured from the 
Qualified vendors and they were authenticated by Dr. P.Jayaraman, Director, Plant Anatomy and 
Research Centre, Tambaram, Chennai.  
Organoleptic characters  
                    Organoleptic character for the raw materials were done with samples taken from the 
suppliers. The results obtained and the standard values are given table 8.1.1   
                              Table 8.1.1 Organoleptic characters 
Name of the plant Nature Colour Odour Taste 
Asparagus racemosus Coarse powder Yellowish brown Characteristic Bitter 
Allium sativum Fine powder Brown Characteristic Astringent 
Lippia  nodiflora Coarse powder Greenish yellow Characteristic Bitter 
Bacopa monneri Coarse powder Light brown Characteristic Bitter 
Oldenlandia heyneii Coarse powder Greenish yellow Characteristic Tasteless  
Smilax zeylanica Coarse powder Brown Characteristic characteristic 
 
 
Preliminary quality control of the raw materials 
                       The raw materials were sampled, authenticated and studied for their compliance to  
Preliminary qualitative standards as established by Indian Pharmacopoeia, Ayurvedic 
Pharmacopoeia of India and other standard references. For those raw materials, for which no 
official standard were available, in house (IH) standards were created and results were compared 
with them. The raw materials were divided into two category viz., Crude herbal drugs and 
Extracts of the crude drugs. Then, they were analyzed for the qualitative and quantitative 
standards. The results were compared with the standard references and observed for its 
compliance. Those materials which met the standards were taken for the formulation and 
development. All the tests were carried out as per the test methods detailed in the materials and 
methods part previously. 
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 Foreign organic matter 
                               Table 8.1.2 Foreign organic matter 
S.No Ingredients Foreign organic 
matter 
Acceptable 
limit(%w/w) 
1 Asparagus racemosus 0.10 ± 0.10 NMT 1% 
2 Allium sativum 0.12 ± 0.11 NMT 2% 
3 Lippia  nodiflora 0.05 ± 0.03 NMT 2% 
4 Bacopa monneri 0.50 ± 0.01 NMT 2 % 
5 Oldenlandia heyneii 0.11 ± 0.13 NMT 1% 
6 Smilax zeylanica 0.05 ± 0.04 NMT 1% 
The value are expressed as mean ±SD, (N= 3); NMT- Not more than,  NLT- Not les than 
 
Loss on drying  
 
           Loss on drying for the raw materials were done. The results obtained and the standared 
values are given table in 8.1.3 
  
                                              Table8.1.3 Loss on drying  
S.No Ingredients Loss on drying 
(%w/w) 
Acceptable 
limit (%w/w) 
1 Asparagus racemosus 3.51 ± 0.38 NMT 10% 
2 Allium sativum 6.10± 0.12 NLT 6 % 
3 Lippia  nodiflora 3.13±  0.32  NMT 4% 
4 Bacopa monneri 2.43 ± 0.01 NMT12% 
5 Oldenlandia heyneii 1.56 ± 0.30 NMT 2 % 
6 Smilax zeylanica 0.35 ± 0.47 NMT 1% 
                 
           The value are expressed as mean±SD,(N=3  ) NMT- Not more than; NLT- Not les than 
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Total ash value 
                Total ash content of raw materials was determined, the values obtained and their 
acceptable limits defined are given in table 8.1.4  
                                                    Table 8.1.4 Total ash value 
S.No Ingredients Total ash value 
(%w/w)  
 
Acceptable 
limit(%w/w) 
1 Asparagus racemosus 4.4 ± 0.50 NMT 15% 
2 Allium sativum 3.5 ± 0.07 NMT 4% 
3 Lippia  nodiflora 2.1 ±  0.10 NMT 10% 
4 Bacopa monneri 2.56 ± 0.12  NMT18% 
5 Oldenlandia heyneii 5.13 ± 0.15 NMT 4 % 
6 Smilax zeylanica 1.12 ± 0.30  NMT 0.6 % 
                       The value are expressed as mean ± SD, (N=3); NMT-Not more than 
Acid insoluble ash  
                 From the total ash content, the acid insoluble ash content of individual raw materials 
was determined and results are enumerated in table 8.1.5 
                                                 Table8.1.5   Acid insoluble ash   
S.No Ingredients Acid insoluble ash 
(%w/w) 
 
Acceptable 
limit (%w/w) 
1 Asparagus racemosus 0.86 ± 0.26 NMT 3% 
2 Allium sativum 0.56 ± 0.13 NMT 1% 
3 Lippia  nodiflora 3.4± 0.26 NMT 5% 
4 Bacopa monneri 2.45± 0.09  NMT6% 
5 Oldenlandia heyneii 9.23± 0.15 NLT 5% 
6 Smilax zeylanica 0.6 ± 0.26 NMT 0.06 % 
     The value are expressed as mean±SD,(N= 3)  NMT- Not more than;  NLT- Not less than. 
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Water soluble ash value 
             From the total ash content, the water soluble ash content of individual raw materials was 
determined and results are enumerated in table 8.1.6 
                                     Table 8.1.6 water soluble ash 
S.No Ingredients Water soluble ash 
(%w/w) 
 
Acceptable 
limit(%w/w) 
1 Asparagus racemosus 2.66± 0.49 NMT 5% 
2 Allium sativum 1.23 ± 0.09 NMT 3% 
3 Lippia  nodiflora 1.46±.025  NLT 4% 
4 Bacopa monneri 4.31± 0.12  NLT 15% 
5 Oldenlandia heyneii 8.23± 0.41 NMT 10 % 
6 Smilax zeylanica 4.33±0.20 NMT 7% 
 
 The value are expressed as mean±SD,(N=3 )NMT- Not more than;    NLT- Not less than 
Sulphated ash value  
     Sulphated ash for the raw materials were determined and results are enumerated in table 8.1.7  
                                Table8.1.7 sulphated ash 
S.No Ingredients Sulphated   ash 
(%w/w) 
 
Acceptable 
limit(%w/w) 
1 Asparagus racemosus 5.16 ± 0.20 NMT 6% 
2 Allium sativum 1.23 ± 0.78 NMT 2 % 
3 Lippia  nodiflora 1.4 ± 0.36 NMT 4 % 
4 Bacopa monneri 1.7 ± 0.65 NLT 2 % 
5 Oldenlandia heyneii 9.0 ± 0.10 NMT 10 % 
6 Smilax zeylanica 4.33 ± 0.20 NMT 5 % 
 
The value are expressed as mean±SD,(N=3) NMT- Not more than;    NLT- Not less than 
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Water soluble Extractive value 
             Extractive values for the raw materials were determined in water and the results are 
tabulated in table 8.1.8 
                          Table 8.1.8 Water soluble Extractive 
S.No Ingredients Water  soluble 
Extractive (%w/w) 
 
Acceptable 
limit(%w/w) 
1 Asparagus racemosus 6.5 ± 0.4 NMT 20 % 
2 Allium sativum 5.12± 0.03  NMT 5% 
3 Lippia  nodiflora 4.33 ± 0.45 NLT 4 % 
4 Bacopa monneri 3.15 ±0.012  NLT 15% 
5 Oldenlandia heyneii 3.53 ± 0.37 NMT 5% 
6 Smilax zeylanica 1.7 ± 0.21 NMT 2% 
The value are expressed as mean ± SD, (N=3 );  NLT- Not less than;  NMT- Not more than 
 
Alcohol soluble extractive value 
            Extractive values for the raw materials were determined in alcohol (90% ethanol) and the 
results are enumerated. Table 8.1.9 
                                       Table 8.1.9 Alcohol soluble extractive 
S.No Ingredients Water  soluble 
Extractive (%w/w) 
 
Acceptable 
limit(%w/w) 
1 Asparagus racemosus 5.36 ± 0.53 NMT15% 
2 Allium sativum 1.01± 0.01 NLT 2.5% 
3 Lippia  nodiflora 11.23 ± 0.25 NLT 4 % 
4 Bacopa monneri 8.12±0.12 NLT 6% 
5 Oldenlandia heyneii 4.5 ± 0.4 NMT 5 % 
6 Smilax zeylanica 2.0 ± 0.05 NMT 3% 
 The value are expressed as mean±SD,(N= 3) NMT- Not more than;      NLT- Not less than 
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 Crude fibre content 
                The crude fibre content for the raw material were determined(duch method) and the 
results are tabulated.Table 8.1.10 
                                    Table8.1.10 Crude fibre content 
S.No Ingredients Crude fibre content 
(%w/w) 
 
1 Asparagus racemosus 0.42 ±0.23 
2 Allium sativum 1.03 ±0.08 
3 Lippia  nodiflora 0.49 ± 0.05 
4 Bacopa monneri 0.91±0.09 
5 Oldenlandia heyneii 0.58 ± 0.28 
6 Smilax zeylanica 0.89 ± 0.11 
                          
                           The value are expressed as mean±SD,(N= 3 ) 
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PHYTOCHEMICAL ANALYSIS  
 
                 The chemical tests for various Phyto constituents in the raw materials were carried out  
and the results were recorded and detailed in Table 8.1.11 
 
 
                                 Table 8.1.11Phytochemical analysis 
 
S.No Chemical 
constituent 
Asparagus 
racemosus 
Bacopa 
monneri 
Allium 
sativum 
Olden 
landia 
heyneii 
Lippia 
nidiflora 
Smilax 
zeylanica 
1  
Carbohydrates 
 
_ _ _ 
 
_ + _ 
2  
Alkaloids 
 
+ + _ + + + 
3  
Steroids 
 
+ + + _ + + 
4  
Glycosides 
 
_ _ _  
+ 
+ _ 
5  
Flavanoids 
 
+ + + + + + 
6  
Tannins 
 
_ _ _ _ + + 
7  
Phenolic 
compounds 
 
_ _ + _ + + 
8  
Proteins 
 
_ _ _ _ _ + 
9  
Terpenoids 
 
_ + + + + + 
10  
Fats and oils 
 
_ _ _ + _ _ 
11 Gums  and 
Mucilage  
 
+ _ _ _ _ _ 
  
      +    present 
- absent 
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 FLUORESCENCE ANALYSIS  
 
     Table 8.1.12 Fluorescence characteristic of powdered samples of Asparagus racemosus 
 
 
S.No Treatment Short UV Ordinary light Long UV 
 
1 Powder 
 
Pale yellow Light brown Light brown 
2 Powder + water 
 
colorless Light brown 
 
Light brown 
3 Powder +Iodine 
 
Dark green Dark green Dark green 
4 Powder +Picric acid 
 
Yellow Dark yellow Green  
5 Powder + NaOH 
 
Greenish yellow Pale white Colorless  
6 Powder +Ethanol 
 
Colorless colorless Colorless  
7 Powder +KOH 
 
Light brown brown Pale yellow 
8 Powder +FeCl3 
 
Greenish yellow brown Black  
9 Powder +Acetic acid 
 
Colorless Pale green Colorless  
10 Powder +Acetone 
 
colorless 
 
light brown Light brown 
11 Powder +Ammonia 
 
Pale yellow Light yellow Colorless 
12 Powder +HCl 
 
colorless 
 
brown Colorless  
13 Powder +H2SO4 
 
Light yellow 
 
Reddish brown Colorless  
14 Powder +HNO3 
 
Light brown 
 
Light brown Light brown 
  
 
 
 
                                                                              RESULTS AND DISCUSSION 
 
Dept. of Pharmacognosy, COP.MMC Page 72 
 
 
 
 
Table 8.1.13 Fluorescence characteristic of powdered samples of Allium sativum 
 
S.No Treatment Short UV Ordinary light Long UV 
 
1 Powder 
 
Light brown Light brown Light brown 
2 Powder + water 
 
Brown  Light brown Brown  
3 Powder +Iodine 
 
Black  Black  Black  
4 Powder +Picric acid 
 
Reddish brown Brown  Reddish brown  
5 Powder + NaOH 
 
Light brown Dark brown Light brown  
6 Powder +Ethanol 
 
Colorless  Light brown Colorless  
7 Powder +KOH 
 
Brown  Reddish brown Brown  
8 Powder +FeCl3 
 
Dark brown Dark black Dark brown 
9 Powder +Acetic acid 
 
Light brown Black  Light brown 
10 Powder +Acetone 
 
Colorless  Light brown Colorless  
11 Powder +Ammonia 
 
Light brown Colorless  Dark brown 
12 Powder +HCl 
 
Colorless Light brown Light black 
13 Powder +H2SO4 
 
Reddish brown Brown  brown 
14 Powder +HNO3 
 
Brown  Colorless  Light brown 
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Table8.1.14 Fluorescence characteristic of powdered samples of Lippia nodiflora 
 
S.No Treatment Short UV Ordinary light Long UV 
 
1 Powder 
 
Pale green Green  Pale green 
2 Powder + water 
 
Pale green Brown  Green 
3 Powder +Iodine 
 
Black  Black  Black 
4 Powder +Picric acid 
 
Pale green Pale green Pale green 
5 Powder + NaOH 
 
Dark green Dark brown Black 
6 Powder +Ethanol 
 
Pale green Pale brown Pale yellow 
7 Powder +KOH 
 
Yellowish green Pale brown Black 
8 Powder +FeCl3 
 
Light green Pale brown Black 
9 Powder +Acetic acid 
 
Green  Dark green Dark green 
10 Powder +Acetone 
 
Pale green Dark green Dark green 
11 Powder +Ammonia 
 
Pale green Dark green Dark green 
12 Powder +HCl 
 
Green  Light green Yellowish green 
13 Powder +H2SO4 
 
Green  Light green Yellowish green 
14 Powder +HNO3 
 
Green  Light green Yellowish green 
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Table 8.1.15 Fluorescence characteristic of powdered samples of Bacopa monnieri 
 
S.No Treatment Short UV Ordinary light Long UV 
 
1 Powder 
 
Green Green Light green 
2 Powder + water 
 
Light green Light green Green 
3 Powder +Iodine 
 
Black Black Black 
4 Powder +Picric acid 
 
Light green Yellowish green Dark green 
5 Powder + NaOH 
 
Light green Dark green Light yellow 
6 Powder +Ethanol 
 
Dark green Dark green Black 
7 Powder +KOH 
 
Yellowish green Black Black 
8 Powder +FeCl3 
 
Light green Light green Black 
9 Powder +Acetic acid 
 
Green Yellowish green Dark green 
10 Powder +Acetone 
 
Yellowish green Brown Dark green 
11 Powder +Ammonia 
 
Light green Light green Yellowish green 
12 Powder +HCl 
 
Green Dark green Yellowish green 
13 Powder +H2SO4 
 
Dark green Dark green Green 
14 Powder +HNO3 
 
Dark green Light green Light yellow 
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Table8.1.16 Fluorescence characteristic of powdered samples of Oldenlandia Heynei 
 
S.No Treatment Short UV Ordinary light Long UV 
 
1 Powder 
 
Pale green Brown Green 
2 Powder + water 
 
Green  Black Black 
3 Powder +Iodine 
 
Black  Light brown Dark green 
4 Powder +Picric acid 
 
Pale green  Light brown Dark green 
5 Powder + NaOH 
 
Dark green Dark brown Black 
6 Powder +Ethanol 
 
Dark green Dark brown Black 
7 Powder +KOH 
 
Yellowish green Light brown Black 
8 Powder +FeCl3 
 
Light green Light brown Dark green 
9 Powder +Acetic acid 
 
Light green Light green Black 
10 Powder +Acetone 
 
Yellowish green Dark green Dark green 
11 Powder +Ammonia 
 
Green Black Yellowish green 
12 Powder +HCl 
 
Green Light green Green  
13 Powder +H2SO4 
 
Light green Light green Light green  
14 Powder +HNO3 
 
Light green Light green Light green 
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Table8.1.17 Fluorescence characteristic of powdered samples of Smilax zeylanica 
S.No Treatment Short UV Ordinary light Long UV 
 
1 Powder 
 
Light brown Brown Brown 
2 Powder + water 
 
Brown Dark brown Dark brown 
3 Powder +Iodine 
 
Dark brown Yellowish brown Light brown 
4 Powder +Picric acid 
 
yellowish green Light brown Brown 
5 Powder + NaOH 
 
Green Dark brown Colorless 
6 Powder +Ethanol 
 
Green Brown Colorless 
7 Powder +KOH 
 
Colorless Dark brown Dark brown 
8 Powder +FeCl3 
 
Light brown Golden yellow Dark brown 
9 Powder +Acetic acid 
 
Light brown Brown Brown 
10 Powder +Acetone 
 
Brown Light brown Colorless 
11 Powder +Ammonia 
 
Light green Colorless Black 
12 Powder +HCl 
 
Colorless Colorless Dark black 
13 Powder +H2SO4 
 
Colorless Brown Colorless 
14 Powder +HNO3 
 
Light brown Light brown Light brown 
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 LIMIT TEST FOR TOTAL HEAVY METALS  
                 
                    The limit test for heavy metals in the raw materials were carried out and the results 
were recorded and detailed in Table 8.1.18 
 
                                     Table 8.1.18 Limit test for heavy metals  
 
 
 
 
 
 
 
 
8.5 MICROBIAL LOAD ANALYSIS:  
               Microbial screening is done for the raw materials were carried out and the results 
obtained were detailed in Table 8.1.19 
                 
                                            Table 8.1.19 Microbial load analysis 
Ingredients parameters Results Limits as per WHO 
 
 
Asparagus racemosus 
Allium sativum 
Lippie nodiflora 
Bacopa monneri 
Oldenlandia heynei 
Smilax zeylanica 
Total Microbial count 
 
100cfu/g NMT 1000cfu/g 
Yeast and mould 
 
Nil NMT 100 cfu/g 
Presence of E.Coli 
 
Absent  Should be absent 
Presence of Salmonella 
 
Absent  Should be absent 
Presence of Shigella 
 
Absent  Should be absent 
Presence of Streptococcus 
 
Absent  Should be absent 
 
S.No Ingredients Results Standard 
 
1 Asparagus racemosus Complies  
 
20 ppm Lead 
2 Allium sativum Complies 
3 Lippia  nodiflora Complies 
4 Bacopa monneri Complies 
5 Oldenlandia heyneii Complies 
6 Smilax zeylanica Complies 
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8.2 PREFORMULATION AND FORMULTION DEVELOPMENT STUDIES  
 
                 Totally five trials of formulation were carried out using different choices of excipients  
Considering different facets of manufacturing problems as well as quality defects in mind. All 
the resultant formulations were evaluated for their flow property, uniformity of filling, 
uniformity of weight, moisture content and disintegration time.  
                                        Table8.2.1 Evaluation of trial batches 
Parameters Trial 1 Trial 2  Trial 3 Trial 4 Trial 5 
Bulk 
density(g/cm
2
) 
0.34±0.026 0.40±0.01 0.41±0.015 0.33±0.04 0.35±0.04 
Tapped 
density(g/cm
2
) 
0.57±0.025 0.54±0.03 0.61±0.02 0.53±0.03 0.57±0.02 
Compressibility 
index (%w/w/) 
40.36±1.12 26.6±2.08 32±2.64 34.6±2.08 33±1.5 
Housner’s ratio 
 
1.4±0.36 1.41±0.01 1.43±0.02 1.53±0.04 1.45±0.03 
Angle of 
repose(degrees) 
34.9±3.35 35.3±3.78 42±1.0 35±1.0 27.6±0.57 
 
                                 Mean ± Standard Deviation (n=3)  
The trial 5 flow properties were within in the range of Excellent and they were in the Specified 
limits. So, fifth trial was chosen for further studies.  
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Table 8.2.2 Angle of Repose, Compressibility Index and Hausner’s Ratio 
 
 
 
 
 
 
 
 
From the data, it was observed that the final trial batch (Trial V) was the ideal one. This batch 
was considered for the optimization and pilot scale up study of that formula was done by 
exercising a large batch size viz., 5000 capsules instead of 500 capsules trials. 
 
8.3 STANDARDISATION OF THE FINISHED PRODUCT  
             The final formulation was analyzed for its quality control parameters in three trials. The 
mean value was obtained and Standard deviation was calculated. Wherever there were no official 
standard, limits for each parameter was established based on trial and error analysis of Trial V 
capsules.   
EVALUATION OF CAPSULES  
1. Description  
                 “light brown ” coloured granules packed in “0” size Red capsules. The polyherbal 
capsules were evaluated for organoleptic characters which include colour, odour, taste and 
nature.  
         Table 8.3.1 Organoleptic characters of capsules 
S.No Parameters Observations 
1 Nature Powder 
2 color Light brown 
3 Odour Slight aromatic 
4 Taste  charecteristic 
Flow property Angle of repose 
in degrees 
Compressibility 
index (CI in %) 
Housner’s ratio 
Excellent 25-30 <10 1.00-1.11 
Good 31-35 11-15 1.12-1.18 
Fair 36-40 16-20 1.19-1.25 
passable 41-45 21-25 1.26-1.34 
poor 46-55 26-31 1.35-1.45 
Very poor 56-65 32-37 1.46-1.59 
Very very poor >65 >38 >1.60 
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Uniformity weight of the capsule 
                           Table 8.3.2Uniformity weight of the capsule 
S.NO Average 
weight/capsule(mg) 
IP specification(mg) 
1 515  
              ±7.5% 2 510 
3 506 
Mean  ± S.D 510.3±4.5 
                     Mean ± standard Deviation(n=20) 
 
 
Disintegration Time  
                                 Table 8.3.3 Disintegration time  
                     
S.NO Disintegration 
time(min) 
IP specification(min) 
1 10.21  
  NMT 30 Minutes 2 10 
3 11 
Mean ± S.D  10’9±0.5 
 
                                       Mean ± Standard Deviation (n=3)  
 
Capsules passed the disintegration test and the results complied as per the I.P.2010  
specification.  
Determination of Moisture Content  
 
                                    Table 8.3.4 Loss on drying  
 
S.NO LOD %w/w IP specification 
1 2.1  
      NMT 5%w/w 2 1.0 
3 2.2 
Mean±S.D 2.1±0.1 
                            Mean ± Standard Deviation (n=3) 
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PHYSICOCHEMICAL PARAMETERS 
  
 P
H
 of the 1%w/v aqueous solution of the formulation  
 
                                           Table 8.3.5 P
H
  
 
S.NO P
H
 IP Specification 
 
1 5.61     
          5-6 2 5.82 
3 5.15 
Mean±S.D 5.52±0.68 
 
                     Mean ± Standard Deviation (n=3) 
 
Determination of Total Ash  
 
                       Table8.3.6 Total Ash  
S.NO Value(%w/w) 
 
1 3.4 
2 4.06 
3 4.01 
Mean ±S.D 3.82±0.36 
   
          Mean ± Standard Deviation (n=3) 
  
Acid insoluble ash 
  
 Table 8.3.7  Acid insoluble ash 
S.NO Value(%w/w) 
 
1 2.16 
2 2.26 
3 2.98 
Mean ±S.D 2.46±0.44 
 
          Mean ± Standard Deviation (n=3) 
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Water soluble ash  
 
 Table 8.3.8 Water soluble ash  
S.NO Value(%w/w) 
 
1 4.09 
2 4.34 
3 3.90 
Mean ±S.D 4.11±0.22 
          Mean ± Standard Deviation (n=3) 
 
Sulphated ash 
  
                        Table 8.3.9 Sulphated ash  
 
S.NO Value(%w/w) 
 
1 3.5 
2 3.9 
3 3.3 
Mean ± S.D 3.5±0.30 
          Mean ± Standard Deviation (n=3) 
  
Determination of Water Soluble Extractive value  
        Water soluble constituents (like Alkaloids, Glycosides, Saponins, Phenols, Gums and  
Carbohydrates) present in the polyherbal formulation were determined. Results were   given in 
Table 8.3.10 
     Table 8.3.10 Water Soluble Extractive value  
S.NO Value(%w/w) 
 
1 3.6 
2 3.9 
3 2.8 
Mean ±S.D 3.4±0.56 
           
 Mean ± Standard Deviation (n=3) 
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Determination of Alcohol Soluble Extractive value:  
 The Alcohol soluble components (like Alkaloids, Proteins, Amino acids and 
Carbohydrates present in the polyherbal formulation were determined as per Pharmacopoeial 
procedure and in-house specifications; results were given in Table  
 
        Table 8.3.11 Alcohol Soluble Extractive value  
S.NO Value(%w/w) 
 
1 1.2 
2 1.8 
3 1.5 
Mean±S.D 1.5±0.3 
  
          Mean ± Standard Deviation (n=3) 
Crude fibre content  
 
                         Table8.3.12 crude fibre content  
S.NO Value(%w/w) 
 
1 21.4 
2 33.3 
3 30.1 
Mean ± S.D 28.26±6.1 
          Mean ± Standard Deviation (n=3) 
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PHYTOCHEMICAL ANALYSIS  
 
1. PRELIMINARY PHYTOCHEMICAL SCREENING  
                   Table8.3.13 Preliminary phytochemical screening  
S.No Chemical 
constituents 
Present(+) in capsule 
powder 
1  
Carbohydrates  
 
+ 
2  
Alkaloids  
 
+ 
3  
Steroids  
 
+ 
4  
Glycosides  
 
+ 
5  
Flavanoids  
 
+ 
6  
Tannins  
 
+ 
7  
Phenolic 
compounds  
 
+ 
8  
Proteins  
 
+ 
9  
Terpenoids  
 
+ 
10  
Fats & oils  
 
+ 
11  
Mucilage and 
gums  
 
+ 
   
The results were established a scientific data which can be used for the identification of the crude 
drugs.  
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FLUORESCENCE ANALYSIS 
             Table 8.3.14   Fluorescence analysis of polyherbal capsules 
S.No Treatment Short UV Ordinary light Long UV 
 
1 Powder 
 
Light green Light brown Colorless 
2 Powder + water 
 
Yellowish green Brown Brown  
3 Powder +Iodine 
 
Black Black Black  
4 Powder +Picric acid 
 
Yellow Light brown Yellowish green 
5 Powder + NaOH 
 
Green Dark brown Dark brown 
6 Powder +Ethanol 
 
Light yellow Blackish brown Dark yellow 
7 Powder +KOH 
 
Light green Brown Black 
8 Powder +FeCl3 
 
Black Light brown Black 
9 Powder +Acetic acid 
 
Light yellow Light brown Yellow 
10 Powder +Acetone 
 
Green Brown Black  
11 Powder +Ammonia 
 
Yellowish green Black Black 
12 Powder +HCl 
 
Yellowish green Light brown Dark brown 
13 Powder +H2SO4 
 
Yellowish green Light brown Dark brown 
14 Powder +HNO3 
 
Green Light brown Dark brown 
 
 
The results were established a scientific data which can be used for the identification of the crude 
drugs.  
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QUANTITATIVE ESTIMATION  
        The Polyherbal formulation was found to contain various phytochemical constituents and  
hence it is desirable to quantify few of them in order to establish a standard to maintain its  
quality. Among them the estimation of total Alkaloids, Saponins, Flavanoids, and Tannin content 
in the aqueous extract were decided to be taken as parameters. Samples were drawn from three 
random samples of polyherbal capsules and the total alkaloids, Saponins, Flavonoids, and Tannin 
content present in them were estimated. The estimated amounts of Alkaloids, Saponins, 
Flavanoids, and Tannins were enumerated in the Table8.3.15  
        Table 8.3.15 Quantitative estimation of phytoconstituent 
 
 
 
 
 
 
 
From the results obtained it is determined that the average content of Alkaloids, Saponins, 
Flavonoids and Tannins were present in the Polyherbal formulation.  
 
 
 
 
 
 
 
 
 
 
 
S.No Parameters Values(%w/w) 
 1 Total Alkaloids 5.44±0.29 
2 Total Saponins 7.77±0.59 
3 Total Tannins 9.96±0.78 
4 Total Flavonoids 3.66±0.36 
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CHROMATOGRAPHIC FINGER PRINTING ANALYSIS 
HPTLC CHROMATOGRAM FOR JW 961-01 MMC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                Fig. 8.3.1 Chromatogrphic finger printing analysis 
 
Result table  
 
       Table 8.3.16 Rf value of the capsules (Chromatogrphic finger printing) 
 
S. No 
 
Rf 
 
Height 
 
Area 
 
Lambda max(nm) 
 1 
 
0.02 
 
42.4 
 
878.1 
 
222 
 2 
 
0.10 
 
4.6 
 
125.6 
 
203 
 3 
 
0.24 
 
3.2 
 
76.3 
 
205 
 4 
 
0.50 
 
1.6 
 
67.0 
 
237 
 5 
 
0.76 
 
1.4 
 
59.6 
 
400 
 6 
 
0.93 
 
0.9 
 
18.6 
 
200 
              Fig. 8.3.1 Chromatogrphic finger printing analysis  
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DETERMINATION OF PESTICIDAL RESIDUE BY TLC  
          The Polyherbal formulation was tested for the presence of any pesticidal residues by thin 
layer chromatography using reference standards. The results obtained from the analysis were 
given in Table 8.3.17 
             Table8.3.17 Determination of Pesticidal Residues 
S.No Pesticide groups                   Pesticides 
Sample I Sample II 
 
1 organophosphorus ND ND 
 
2 carbamates ND ND 
 
 
 
                                  ND –No spots were detected  
From the results it can be concluded that the formulations were safer as there is no traceable limit 
of pesticides present in them.  
 
HEAVY METALS ANALYSIS  
            Capsules were analyzed for the heavy metals which include Arsenic, Lead and Mercury. 
The results are as follows:  
                         Table 8.3.18 Heavy metals analysis 
S.No Parameters Results Limits as per WHO 
1 Arsenic 0.05 ppm MNT5ppm 
2 Lead 0.3 ppm NMT10ppm 
3 Mercury 0.001 ppm NMT0.5ppm 
 
From the results it is shown that the Polyherbal formulation complies with the heavy metals 
limits of the WHO guidelines and hence it is safe to be taken internally.  
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MICROBIAL LOAD ANALYSIS:  
             Microbial screening is done for the Polyherbal formulation from the fresh packs of the  
Same Batch and the results obtained were detailed in Table8.3.19. 
 
 
                                Table 8.3.19 Microbial load analysis 
S.No Parameters Results Limits as per WHO 
1 Total Microbial Count 
  
 
110 cfu/g NMT 1000 cfu/g 
2 Yeast and Mould Nil NMT 100 cfu/g 
3 E.Coli Absent Should be absent 
4 Salmonella Absent Should be absent 
5 Shigella Absent Should be absent 
6 Streptococcus  Absent Should be absent 
 
                             (Note: cfu – Colony forming units)  
From the results, it is shown that the formulation complies with the WHO standards for  
Microbial load analysis and hence it is safer to be taken internally.  
 
8.4 ACCELERATED STABILITY STUDIES  
 
  Table 8.4.1 Organoleptic parameters of capsules during the stability period 
Parameters Initial study 30 days 60 days 90 days 
 
Nature  Powder NC NC NC 
Color Brown NC NC NC 
Odour  Slight aromatic NC NC NC 
Taste charetristic NC NC NC 
  
                                                 NC-No Change 
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                                      Table 8.4.2 Quality control test 
Parameters                       Stability period 
After 1 month After 2 month After 3 month 
Uniformity of weight 511.8±2.88mg 515.4±1.34mg 515.6±0.56mg 
Loss on drying 3.1± 0.26%w/w 3.8±0.12%w/w 3.5±0.06%w/w 
Disintegration test 9’24”±0.25 8’56”±0.34 8’14”±0.65 
P
H
 5.5±0.49 5.7±0.28 5.8±0.43 
Total ash 5.1±0.31%w/w 5.3±0.59%w/w 5.5±0.05%w/w 
Acid insoluble ash 6.3±0.02%w/w 6.0±0.16%w/w 6.5±0.56%w/w 
Water soluble ash 4.6±0.05%w/w 5.2±0.03%w/w 5.3±0.91%w/w 
Sulphated ash 3.2±0.26%w/w 3.9±0.65%w/w 3.5±0.03%w/w 
Water soluble extractive 
value 
2.8±0.30%w/w 3.0±0.97%w/w 3.1±1.24%w/w 
Alcohol soluble extractive 1.53±0.35%w/w 1.59±0.56%w/w 1.56±0.47%w/w 
Crude fibre content 30.1±0.35%w/w 31.34±0.34%w/w 31.29±0.74%w/w 
Total alkaloid content 5.43±0.43%w/w 5.98±0.85%w/w 5.34±0.54%w/w 
Total saponin content 7.39±0.05%w/w 7.90±0.45%w/w 7.91±0.86%w/w 
Total tannin content 9.45±0.45%w/w 9.13±0.18%w/w 9.78±0.83%w/w 
Total flavonoid content 3.85±0.02%w/w 3.46±0.62%w/w 3.45±0.32%w/w 
The values are expressed as mean ± SD. N=3 
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MICROBIAL LOAD ANALYSIS 
                                              Table 8.4.3 Microbial load analysis 
S.No parameters                                Results specification 
Initial study After 1 month After 3 month 
1 Total Microbial 
Count 
  
 
110cfu/g 110cfu/g 120cfu/g NMT 1000cfu/g 
2 Yeast and Mould Nil  Nil  Nil  NMT 100cfu/g 
3 E.Coli absent absent absent Should be absent 
4 Salmonella absent absent absent Should be absent 
5 Shigella absent absent absent Should be absent 
6 Streptococcus  absent absent absent Should be absent 
 All the data shows that the formulation is stable under accelerated stability conditions 
 
 
8.5 PHARMACOLOGICAL STUDIES 
In-vitro anti arthritic activity 
                          Table 8.5.1 In-vitro anti arthritic activity of extract of Asparagus racemosus 
Assay Percentage inhibition at different concentrations 
100µg 200µg 400µg 800µg 200µg(std) 
Protein 
denaturation 
60.83±0.30 76.52±0.05 80.33±0.42 86.27±0.83 87.12±0.51 
Inhibition of 
protenase 
enzyme 
67.10±0.26 72.91±0.41 76.42±0.18 80.52±0.19 81.53±0.17 
Membrane 
stabilization 
59.29±0.16 65.38±0.71 74.84±0.73 81.89±0.35 86.13±1.34 
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The values are expressed as mean ± SD. N=3. 
 
 
Fig 8.5.1 Graphical representation of in vitro anti arthritic activity extract of  asparagus 
racemosus 
PDA- Protein denaturation assay 
IPA- Inhibition of protenase enzyme activity 
MSA- Membrane stabilization assay 
         The extract of Asparagus racemosus showed a dose dependent inhibitory activity on 
protein denaturation, protenase enzyme and membrane lysis. The protein denaturation, protenase 
enzyme and membrane stabilization was maximum at the concentration 800µg 
(86.27%,80.52%,81.89%) which was less than the standard drug, diclofenac sodium 200 
µg(87.12%,81.53%,86.13%). 
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Table 8.5.2 In-vitro anti arthritic activity of extract of allium sativum 
Assay Percentage inhibition at different concentrations 
100µg 200µg 400µg 800µg 200µg(std) 
Protein 
denaturation 
52.76±1.42 62.39±1.39 72.76±1.15 75.28±1.32 81.32±0.32 
Inhibition of 
protenase 
enzyme 
64.29±0.17 69.36±1.72 74.42±0.09 76.28±0.15 79.49±0.16 
Membrane 
stabilization 
55.72±0.64 60.43±0.48 66.32±0.52 78.43±0.26 83.92±0.31 
The values are expressed as mean ± SD.n=3 
 
Fig 8.5.2 Graphical representation of invitro anti arthritic extract of allium sativum  
           The extract of Allium sativum showed a dose dependent inhibitory activity on protein 
denaturation, protenase enzyme and membrane lysis. The protein denaturation, protenase 
enzyme and membrane stabilization was maximum at the concentration 800µg (75.28%, 76.28%, 
78.43%) which was less than the standard drug, diclofenac sodium 200 
µg(81.32%,79.49%,83.92%). 
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Table 8.5.3 In-vitro anti arthritic activity of extract of  Bacopa monneri 
Assay Percentage inhibition at different concentrations 
100µg 200µg 400µg 800µg 200µg(std) 
Protein 
denaturation 
60.32±0.25 72.84±1.39 79.43±1.15 84.32±0.95 85.43±0.49 
Inhibition of 
protenase 
enzyme 
56.29±0.38 60.37±0.19 65.39±0.95 74.32±0.15 78.48±1.15 
Membrane 
stabilization 
63.21±1.43 70.29±0.48 74.39±0.15 79.53±0.48 81.43±0.86 
The values are expressed as mean ± SD. N=3 
 
 
Fig8.5.3 Graphical representation of in vitro anti arthritic extract of Bacopa monneri   
 
        The extract of Bacopa monneri showed a dose dependent inhibitory activity on protein 
denaturation, protenase enzyme and membrane lysis. The protein denaturation, protenase 
enzyme and membrane stabilization was maximum at the concentration 800µg (84.32%, 74.32%, 
79.53%) which was less than the standard drug, diclofenac sodium 200 
µg(85.43%,78.48%,81.43%). 
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Table 8.5.4  In-vitro anti arthritic activity of extract of Lippia nodiflora 
Assay Percentage inhibition at different concentrations 
100µg 200µg 400µg 800µg 200µg(std) 
Protein 
denaturation 
74.73±0.32 79.93±0.31 81.73±0.37 85.93±0.73 86.32±0.48 
Inhibition of 
protenase 
enzyme 
69.38±0.38 74.31±0.65 77.83±0.28 79.53±0.65 83.65±0.41 
Membrane 
stabilization 
57.38±0.48 61.26±0.29 66.73±0.37 71.42±0.72 74.29±1.13 
The values are expressed as mean ± SD. N=3 
 
 
Fig 8.5.4Graphical representation of in vitro anti arthritic extract of Lippia nodiflora  
           The extract of Lippia nodiflora showed a dose dependent inhibitory activity on protein 
denaturation, protenase enzyme and membrane lysis. The protein denaturation, protenase 
enzyme and membrane stabilization was maximum at the concentration 800µg (85.93%, 79.53%, 
71.42%) which was less than the standard drug, diclofenac sodium 200 
µg(86.32%,83.65%,74.29%). 
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Table8.5.5 in-vitro anti arthritic activity of extract of Oldenlandia heynei 
Assay Percentage inhibition at different concentrations 
100µg 200µg 400µg 800µg 200µg(std) 
Protein 
denaturation 
70.36±0.16 75.38±0.32 79.49±0.39 82.48±0.47 85.93±0.05 
Inhibition of 
protenase 
enzyme 
68.43±0.39 72.48±0.54 76.48±0.65 80.48±0.82 81.38±0.18 
Membrane 
stabilization 
61.38±0.02 67.38±0.29 70.37±0.03 72.48±0.28 74.29±0.19 
The values are expressed as mean ± SD. N=3 
 
Fig 8.5.5 Graphical representation of in vitro anti arthritic extract of Oldenlandia heynei  
 
           The extract of Oldenlandia heynei showed a dose dependent inhibitory activity on protein 
denaturation, protenase enzyme and membrane lysis. The protein denaturation, protenase 
enzyme and membrane stabilization was maximum at the concentration 800µg (82.48%, 80.48%, 
72.48%) which was less than the standard drug, diclofenac sodium 200 
µg(85.93%,81.38%,74.29%). 
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Table 8.5.6  in-vitro anti arthritic activity of extract of Smilax zeylanica 
Assay Percentage inhibition at different concentrations 
100µg 200µg 400µg 800µg 200µg(std) 
Protein 
denaturation 
70.35±0.35 72.38±0.32 75.29±0.17 82.43±0.04 82.57±0.02 
Inhibition of 
protenase 
enzyme 
70.41±0.37 75.37±0.04 80.38±0.26 86.73±0.17 87.36±0.37 
Membrane 
stabilization 
64.28±0.93 69.36±0.07 73.72±0.64 75.38±0.08 81.39±1.15 
The values are expressed as mean ± SD. N=3 
 
 
Fig 8.5.6 Graphical representation of in vitro anti arthritic extract of Smilax zeylanica 
             The extract of Smilax zeylanica showed a dose dependent inhibitory activity on protein 
denaturation, protenase enzyme and membrane lysis. The protein denaturation, protenase 
enzyme and membrane stabilization was maximum at the concentration 800µg (82.43%, 86.73%, 
75.38%) which was less than the standard drug, diclofenac sodium 200 
µg(82.57%,87.36%,81.39%) 
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Table 8.5.7In vitro antioxidant and anti arthritic activity of polyherbal capsule formulation 
Assay              Percentage inhibition at different concentrations 
100µg 200µg 400µg 800µg 200µg(std) 
Protein denaturation 45.32±0.42 51.23±0.12 65.84±0.84 74.92±0.43 78.34±0.56 
Inhibition of protenase 
enzyme 
54.23±0.22 59.21±0.45 69.43±0.67 76.43±0.47 80.32±0.34 
Membrane stabilization 43.23±0.49 49.39±0.34 58.30±0,40 68.32±0.11 72.49±0.19 
Reducing power assay 42.48±0.05 52.24±0.84  
 
65.43±0.43  
 
71.53±0.32  
 
72.43±0.56  
 
Nitric oxide scavenging 
assay 
40.53±0.47  
 
51.38±0.48  
 
69..85±0.36  
 
74.27±1.38  
 
75.94±0.75  
 
The values are expressed as mean ± SD. N=3 
 
Fig 8.5.7: Graphical representation of anti oxidant and anti arthritic activity of poly herbal 
formulation of the capsules 
           The antioxidant activity of capsules showed a dose dependent inhibitory of reducing 
power assay and nitric oxide scavenging assay. The reducing power assay and nitric oxide 
scavenging assay was maximum at the concentration 800µg (71.53%, 74.27%, ) which was less 
than the standard drug, ascorbic acid 200 µg(72.43%,75.94%) 
0
10
20
30
40
50
60
70
80
90
RPA NOSA PDA IPA MSA
100µg
200µg
400µg
800µg
200µg(std)
                                                                              RESULTS AND DISCUSSION 
 
Dept. of Pharmacognosy, COP.MMC Page 99 
 
 
8.6ACUTE TOXICITY STUDY 
       Table 8.6.1 Behavioural and physical observation of polyherbal formulation treated rats 
(2000mg/kg body weight) 
OBSERVATION 30 mins 4 hrs 24 hrs 14
th
 day 
Body weight No change No change No change No change 
Preterminal deaths Absent  Absent  Absent  Absent  
Cage side observation Normal  Normal  Normal  Normal  
Motor activity Normal  Normal  Normal  Normal  
Convulsions Absent  Absent  Absent  Absent  
Piloerection Absent  Absent  Absent  Absent  
Righting reflex Present  Present  Present  Present  
Lacrimation Normal  Normal  Normal  Normal  
Salivation Normal  Normal  Normal  Normal  
Respiration Normal  Normal  Normal  Normal  
Skin color Normal  Normal  Normal  Normal  
Diarrhoea  Absent  Absent  Absent  Absent  
Loss of corneal reflex Normal  Normal  Normal  Normal  
Loss of pinnal reflex Normal  Normal  Normal  Normal  
Grooming  Absent  Absent  Absent  Absent  
Sedation  Normal  Normal  Normal  Normal  
Excitation  Normal  Normal  Normal  Normal  
Aggression  Normal  Normal  Normal  Normal  
The results of acute toxicity study are shown in table   .There were no morbidity and mortality 
observed for polyherbal formulation treated animals upto 2000 mg/kg. 
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8.7 INVIVO ANTIARTHRITIC ACTIVITY 
Table8.7.1 Changes in paw swelling (paw circumferences in mm) 
Treatment  Group I Group II Group III Group IV Group V 
0
th 
day 0.32±0.015 0.33±0.020 0.45±0.02
ab
 0.51±0.03
ab
 0.52±0.026
ab
 
4
th
 day 0.30±0.004
b
 0.49±0.014
a
 0.35±0.02
b
 0.45±0.021
a
 0.45±0.03
a
 
8
th
 day 0.31±0.006
b 
0.48±0.017
a 
0.28±0.03
b
 0.37±0.033
b
 0.37±0.027
b1
 
14
th
  day 0.30±0.001
b
 0.52±0.015
a
 0.23±0.02
b
 0.30±0.03
b
 0.23±0.02
b
 
21th day 0.32±0.01
b
 0.53±0.014
a
 0.17±0.02
ab
 0.21±0.029
a1b
 0.19±0.041
ab
 
The values are expressed as mean ±SD, (n=6).  
a 
P<0.01 as compared to control ;   
a1
P<0.05 as compared to control 
 
b 
P<0.01 as compare to arthritic control ; 
b1
P<0.05 as compare to arthritic control    
 The data was analyzed using one way analysis of variance (ANOVA) followed by Dennett’s test. P 
values <0.01 were considered as Significant.  
 
 
 
Fig  8.7.1 The graphical representation of paw swelling changes in study groups  
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  Table 8.7.2 Changes in body weight(g) 
Treatment  Group I Group II Group III Group IV Group V 
0
th 
day 169.17±4.42
b
 134.14±4.92
a
 137.50±4.45
b
 150.83±2.58 121.67±6.68
b
 
4
th
 day 171.67±4.45 125.00±4.59
a
 145.83±2.54 158.67±1.28
b
 124.33±4.65
a
 
8
th
 day 171.33±4.42
b
 122.50±4.82
a
 148.33±2.27 162.17±0.90
b
 128.33±4.25
a
 
14
th
  day 174.00±4.76
b
 120.0±5.34
a
 151.5±2.22
b1
 165.0±0.89
ab
 133.5±4.00
a
 
21th day 175.17±4.06
b
 115.83±5.65
a
 153.50±2.06
b
 168.33±0.65
b
 137.00±3.63
a1
 
The values are expressed as mean ±SD, (n=6).    
 
a 
P<0.01 as compared to control ;   
a1
P<0.05 as compared to control 
 
b 
P<0.01 as compare to arthritic control ; 
b1
P<0.05 as compare to arthritic control 
The data was analyzed using one way analysis of variance (ANOVA) followed by Dennett’s test. P values 
<0.01 were considered as Significant.  
 
 
 
 
Fig 8.7.2    The graphical representation of body weight changes in study groups 
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 Table 8.7.3 Percent inhibition of paw swelling 
Treatment  4
th
 day 8
th
 day 14
th
 day 21
st
 day 
Group III 35.24±0.15 39.55±2.23 65.32±0.21 72.32±1.23 
Group IV 24.56±1.32 29.32±1.42 48.13±1.42 54.75±2.53 
Group V 30.45±2.90 41.23±1.03 50.32±1.32 69.64±1.17 
The values are expressed as mean ±SD, (n=6).    
  
 
Fig 8.7.3 The graphical representation of percentage inhibition of paw swelling 
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8.8 HEMATOLOGICAL PARAMETERS 
  Table8.8.1 Hematological parameters 
parameters Group I Group II Group III Group IV Group IV 
WBC(Cells/cumm) 6.5±0.3 7.4± 0.41 7.1±0.32 6.9±0.83 6.4±0.2 
RBC(Cells/cumm) 6.48±0.21 5.83±0.13 6.14±0.22 6.03±0.63 6.76±0.02 
DC-lymphocytes 24.8±0,42 50.2±0.42 36.9±0.38 35.0±0.45 30.49±0.05 
DC- monocytes 4.12±0.14 3.26±0.32 5.32±0.87 3.65±0.39 4.83±0.01 
DC- eosinophils 1.34±0.12 2.45±0.74 1.55±0.34 1.33±0.08 1.39±0.17 
DC- neutrophils 71.34±0.14 46.12±0.43 57.32±12 61.34±0.41 65.21±0.18 
PCV(%) 33.2±0.32 24.8±0.04 32.3±0.54 33.16±0.64 36.93±0.74 
ESR(mm/hrs) 
30 min 
2.32±0.02 1.3±0.32 1.1±0.21 3.02±0.07 2.12±0.77 
60 mins 5.12±0.28 21.9±1.21 6.42±0.42 4.5±0.35 5.76±0.09 
Hb(g/dl) 11.3±0.45 9.4±0.61 10.35 10.0±0.07 11.9±0.57 
The values are expressed as mean ±SD, (n=6).     
            Hematological parameters did not shows any difference between the polyherbal 
formulation treated groups, diclofenac sodium treated group and normal control. The arthritic 
control group there was elevated in Erythrocyte Sedimentation Rate and Reduce Haemoglobin, 
Red Blood cell, Differential Count on comparing with normal control. This shows that the 
polyherbal formulation does not affect the hematological parameters. 
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8.9 RADIOGRAPHIC STUDY 
Fig8.9.1 Radiographic hind leg image of control group rat 
 
 
 
  Fig8.9.2 Radiographic hind leg image of arthritic control group rat 
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  Fig 8.9.3 Radiographic hind leg image of Diclofenac sodium (std) treated group rat 
 
  
 
Fig 8.9.4   Radiographic hind leg image of Test drug I treated group rat 
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    Fig 8.9.5 Radiographic hind leg image of test drug II treated group rat 
Report: 
     Control:  No lesion 
     Arthritic control:  
                     Severe arthritis changes noticed in ankle joint and space lesion also  noticed. 
     Standard:  
                  Mild arthritis changes seen in ankle joint. 
    Test drug I and II:   
                  Radiographically no abnormalities of knee joint ankle joint seen both test drug treated 
group. 
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8.10 HISTOPATHOLOGICAL EXAMINATION  OF BONE: 
                                                                                                                                                                
                    
Fig 8.10.1 Examination of bone of control group        Fig 8.10.2 Examination of bone of      
                                                                                            arthritic control group 
 
                                                  
                          Fig 8.10.3 Examination of bone of diclofenac sodium treated group 
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Fig 8.10.4Examination of bone of  test drug I      Fig 8.10.5 Examination of bone of  test drug II 
 
Result: 
Control: 
            No abnormality detected 
Arthritic control: 
            Severe erosion of cartilage 
Standard : 
            No abnormality detected 
Test drug I:  
            Mild erosion of cartilage 
Test drug II 
            Mild synovial hyperplasia 
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                                      9. SUMMARY AND CONCLUSION 
            The present study was attempt to development, standardization and pharmacological 
activity of anti arthritic polyherbal formulation. 
           Based on the extensive review of  literature, six active ingredients were selected for the 
formulation of  polyherbal capsules to treat rheumatoid arthritis. 
           The raw materials which are procruded from TTK Health care Ltd are subjected to 
various raw material analysis for their identy, quality and purity. The materials which complied 
with the specification were taken for further studies 
           Preformulation studies such as bulk density, tapped density, compressibility index, 
housner’s ratio and angle of repose were done for the all raw materials. 
           From the preformulation studies best batches was selected to formulate capsules.  
            The formulated capsules were standardized as per WHO guidelines using various 
parameters and include quantification of phytoconstituent, HPTLC, Heavy metals. Stability 
studies of the capsules are carried out as per ICH guidelines. 
           Pharmacological studies (both in vitro and in vivo) were carried out to study the efficacy 
of the formulation in the treatment of rheumatoid arthritis and in vitro Anti oxidant activity of  
formulated capsule also done. 
          The extract of asparagus racemosus showed the protein denaturation, protenase enzyme 
and membrane stabilization was maximum at the concentration 800µg (86.27%,80.52%,81.89%) 
which was less than the standard drug, diclofenac sodium 200 µg(87.12%,81.53%,86.13%). 
          The extract of allium sativum showed the protein denaturation, protenase enzyme and 
membrane stabilization was maximum at the concentration 800µg (75.28%, 76.28%, 78.43%) 
which was less than the standard drug, diclofenac sodium 200 µg(81.32%,79.49%,83.92%). 
          The extract of Bacopa monneri showed the protein denaturation, protenase enzyme and 
membrane stabilization was maximum at the concentration 800µg (84.32%, 74.32%, 79.53%) 
which was less than the standard drug, diclofenac sodium 200 µg(85.43%,78.48%,81.43%). 
            The extract of Lippia nodiflora showed the protein denaturation, protenase enzyme and 
membrane stabilization was maximum at the concentration 800µg (85.93%, 79.53%, 71.42%) 
which was less than the standard drug, diclofenac sodium 200 µg(86.32%,83.65%,74.29%). 
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           The extract of Oldenlandia heynei showed the protein denaturation, protenase enzyme and 
membrane stabilization was maximum at the concentration 800µg (82.48%, 80.48%, 72.48%) 
which was less than the standard drug, diclofenac sodium 200 µg(85.93%,81.38%,74.29%). 
           The extract of Smilax zeylanica showed The protein denaturation, protenase enzyme and 
membrane stabilization was maximum at the concentration 800µg (82.43%, 86.73%, 75.38%) 
which was less than the standard drug, diclofenac sodium 200 µg(82.57%,87.36%,81.39%). 
          The antioxidant activity of capsules showed the reducing power assay and nitric oxide 
scavenging assay was maximum at the concentration 800µg (71.53%, 74.27%, ) which was less 
than the standard drug, ascorbic acid 200 µg(72.43%,75.94%). 
          Acute toxicity studies were performed according to OECD guidelines and for invivo 
studies was fixed. 
          Invivo studies using complete freund’s adjuvants induced model was done in rats. The test 
drug shows results are body weight, paw swelling, hematologic, histopathologic and 
radiographic study was done. 
          Body weight of rat increased in polyherbal formulation treated groups and also diclofenac 
in the diclofenac treated groups. There was a statistically significance increase the body weight, 
in the polyherbal formulation treated groups on comparing with arthritic control group. 
          The paw swelling showed a decrease in polyherbal formulation treated groups and also 
diclofenac sodium treated group. There was a statistically significance decrease the paw swelling  
in the polyherbal formulation treated groups on comparing with arthritic control group.  
            Hematological parameters did not shows any difference between the polyherbal 
formulation treated groups, diclofenac sodium treated group and normal control. The arthritic 
control group there was elevated in RBC, DC, ESR and Hb on comparing with normal control. 
This shows that the polyherbal formulation does not affect the hematological parameters. 
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              Histopathologic examination of the joint showed severe cartilage erosion in arthritic 
control group compared with polyherbal formulation treated group and diclofenac sodium treated 
group. This shows that polyherbal formulation suppressed the inflammation changes associated 
with arthritis which was equivalent to diclofenac sodium. 
            Radiographic study showed mild lesion in polyherbal formulation and standard drug 
treated group compared to arthritic control group having severe arthritic change. This shows that 
polyherbal formulation suppressed the inflammation changes associated with arthritis which was 
equivalent to diclofenac sodium. 
       Future studies can be directed towards the exact mechanism of action responsible for this 
anti arthritic activity and further the study can be extended for clinical trials also.  
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